William Oh, MD, FACS

Title(s)Assistant Clinical Professor, Surgery
SchoolSchool of Medicine
AddressLocation Required, #001
Varies CA 00000
Phone559-499-6400
ORCID ORCID Icon0000-0001-5113-8147 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Cornel UniversityBS2008Human Biology, Health, and Society
    New York Medical CollegeMD2013Medicine
    University of California San Francisco, FresnoResidency2018General Surgery
    Indiana Colon and Rectal Specialists/Indiana UniversityFellowship2019Colon and Rectal Surgery

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Risk Factors for Early Treatment Discontinuation Due to Toxicity Among Patients With Metastatic Castration-resistant Prostate Cancer Receiving Androgen Receptor-targeted Therapy. Am J Clin Oncol. 2024 Feb 12. Chakrani Z, Mellgard G, Saffran N, McCroskery S, Taylor N, Patel M, Liaw B, Galsky M, Oh WK, Tsao CK, Patel VG. PMID: 38344754.
      View in: PubMed   Mentions:    Fields:    
    2. Routine versus no assessment of gastric residual volumes in preterm infants receiving enteral feeding via intermittent feeding tubes: a randomized controlled trial. J Matern Fetal Neonatal Med. 2023 Dec; 36(1):2211200. Williams S, Bostain R, Couch N, Kamdar T, Oh W, Thompson L, Pepe J, Yi F, Dereddy N. PMID: 37156548.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    3. Antenatal Steroids, Prophylactic Indomethacin, and the Risk of Spontaneous Intestinal Perforation. J Pediatr. 2023 08; 259:113457. Laptook AR, Weydig H, Brion LP, Wyckoff MH, Arnautovic TI, Younge N, Oh W, Chowdhury D, Keszler M, Das A, National Institute of Child Health and Human Development Neonatal Research Network. PMID: 37172814; PMCID: PMC10524442.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    4. Biomarker Development Trial of Satraplatin in Patients with Metastatic Castration-Resistant Prostate Cancer. Oncologist. 2023 04 06; 28(4):366-e224. Liaw BC, Tsao CK, Seng S, Jun T, Gong Y, Galsky MD, Oh WK. PMID: 36519763; PMCID: PMC10078918.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    5. Analysis of real-world data to investigate evolving treatment sequencing patterns in advanced non-small cell lung cancers and their impact on survival. J Thorac Dis. 2023 May 30; 15(5):2438-2449. Liu Z, Lee K, Cohn D, Zhang M, Ai L, Li M, Zhang X, Jun T, Higashi MK, Pan Q, Oh W, Stolovitzky G, Schadt E, Wang X, Li SD. PMID: 37324065; PMCID: PMC10267939.
      View in: PubMed   Mentions: 1  
    6. Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. Eur J Cancer. 2023 05; 185:178-215. Gillessen S, Bossi A, Davis ID, de Bono J, Fizazi K, James ND, Mottet N, Shore N, Small E, Smith M, Sweeney CJ, Tombal B, Antonarakis ES, Aparicio AM, Armstrong AJ, Attard G, Beer TM, Beltran H, Bjartell A, Blanchard P, Briganti A, Bristow RG, Bulbul M, Caffo O, Castellano D, Castro E, Cheng HH, Chi KN, Chowdhury S, Clarke CS, Clarke N, Daugaard G, De Santis M, Duran I, Eeles R, Efstathiou E, Efstathiou J, Ekeke ON, Evans CP, Fanti S, Feng FY, Fonteyne V, Fossati N, Frydenberg M, George D, Gleave M, Gravis G, Halabi S, Heinrich D, Herrmann K, Higano C, Hofman MS, Horvath LG, Hussain M, Jereczek-Fossa BA, Jones R, Kanesvaran R, Kellokumpu-Lehtinen PL, Khauli RB, Klotz L, Kramer G, Leibowitz R, Logothetis C, Mahal B, Maluf F, Mateo J, Matheson D, Mehra N, Merseburger A, Morgans AK, Morris MJ, Mrabti H, Mukherji D, Murphy DG, Murthy V, Nguyen PL, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Pezaro CJ, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin MA, Ryan CJ, Saad F, Sade JP, Sartor O, Scher HI, Sharifi N, Skoneczna I, Soule H, Spratt DE, Srinivas S, Sternberg CN, Steuber T, Suzuki H, Sydes MR, Taplin ME, Tilki D, Türkeri L, Turco F, Uemura H, Uemura H, Ürün Y, Vale CL, van Oort I, Vapiwala N, Walz J, Yamoah K, Ye D, Yu EY, Zapatero A, Zilli T, Omlin A. PMID: 37003085.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    7. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. Eur Urol. 2023 03; 83(3):267-293. Gillessen S, Bossi A, Davis ID, de Bono J, Fizazi K, James ND, Mottet N, Shore N, Small E, Smith M, Sweeney C, Tombal B, Antonarakis ES, Aparicio AM, Armstrong AJ, Attard G, Beer TM, Beltran H, Bjartell A, Blanchard P, Briganti A, Bristow RG, Bulbul M, Caffo O, Castellano D, Castro E, Cheng HH, Chi KN, Chowdhury S, Clarke CS, Clarke N, Daugaard G, De Santis M, Duran I, Eeles R, Efstathiou E, Efstathiou J, Ngozi Ekeke O, Evans CP, Fanti S, Feng FY, Fonteyne V, Fossati N, Frydenberg M, George D, Gleave M, Gravis G, Halabi S, Heinrich D, Herrmann K, Higano C, Hofman MS, Horvath LG, Hussain M, Jereczek-Fossa BA, Jones R, Kanesvaran R, Kellokumpu-Lehtinen PL, Khauli RB, Klotz L, Kramer G, Leibowitz R, Logothetis CJ, Mahal BA, Maluf F, Mateo J, Matheson D, Mehra N, Merseburger A, Morgans AK, Morris MJ, Mrabti H, Mukherji D, Murphy DG, Murthy V, Nguyen PL, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Pezaro C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin MA, Ryan CJ, Saad F, Pablo Sade J, Sartor OA, Scher HI, Sharifi N, Skoneczna I, Soule H, Spratt DE, Srinivas S, Sternberg CN, Steuber T, Suzuki H, Sydes MR, Taplin ME, Tilki D, Türkeri L, Turco F, Uemura H, Uemura H, Ürün Y, Vale CL, van Oort I, Vapiwala N, Walz J, Yamoah K, Ye D, Yu EY, Zapatero A, Zilli T, Omlin A. PMID: 36494221; PMCID: PMC7614721.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    8. Effects of lipid emulsions on unbound bilirubin and response to phototherapy in preterm infants. J Matern Fetal Neonatal Med. 2022 Dec; 35(26):10395-10400. Sasenick J, Kleinfeld A, Huber A, Oh W, Hegyi T, Weinberger B. PMID: 36176060; PMCID: PMC9852034.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    9. Management of de novo metastatic hormone-sensitive prostate cancer: A comprehensive report of a single-center experience. PLoS One. 2022; 17(8):e0264800. Guin S, Liaw BK, Jun T, Ayers K, Patel B, O'Connell T, Deitz M, Klein M, Mullaney T, Prentice T, Newman S, Fink M, Zhou X, Schadt EE, Chen R, Oh WK. PMID: 35984843; PMCID: PMC9390935.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    10. Clinical factors associated with outcome in solid tumor patients treated with immune-checkpoint inhibitors: a single institution retrospective analysis. Discov Oncol. 2022 Aug 12; 13(1):73. Qin Q, Jun T, Wang B, Patel VG, Mellgard G, Zhong X, Gogerly-Moragoda M, Parikh AB, Leiter A, Gallagher EJ, Alerasool P, Garcia P, Joshi H, Galsky M, Oh WK, Tsao CK. PMID: 35960456; PMCID: PMC9374856.
      View in: PubMed   Mentions: 3  
    11. Effect of concurrent beta-blocker use in patients receiving immune checkpoint inhibitors for advanced solid tumors. J Cancer Res Clin Oncol. 2023 Jul; 149(7):2833-2841. Mellgard G, Patel VG, Zhong X, Joshi H, Qin Q, Wang B, Parikh A, Jun T, Alerasool P, Garcia P, Gogerly-Moragoda M, Leiter A, Gallagher EJ, Oh WK, Galsky MD, Tsao CK. PMID: 35788726; PMCID: PMC10739778.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    12. Does Circulating Tumor DNA Measure Up to Prostate-Specific Antigen? JAMA Oncol. 2022 07 01; 8(7):972-974. Jun T, Oh WK. PMID: 35551363.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    13. Global DNA methylation of WTC prostate cancer tissues show signature differences compared to non-exposed cases. Carcinogenesis. 2022 06 27; 43(6):528-537. Yu H, Tuminello S, Alpert N, van Gerwen M, Yoo S, Mulholland DJ, Aaronson SA, Donovan M, Oh WK, Gong Y, Wang L, Zhu J, Taioli E. PMID: 35239955; PMCID: PMC9234756.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    14. Maternal Body Mass Index and Risk of Bronchopulmonary Dysplasia in Extremely Preterm Infants. Am J Perinatol. 2022 Jun 27. Mayor R, Mora A, Carmona C, Du Y, Pepe J, Fritz K, Oh W. PMID: 35240704.
      View in: PubMed   Mentions:    Fields:    
    15. Targeted Next-Generation Sequencing Reveals Exceptionally High Rates of Molecular Driver Mutations in Never-Smokers With Lung Adenocarcinoma. Oncologist. 2022 06 08; 27(6):476-486. Mack PC, Klein MI, Ayers KL, Zhou X, Guin S, Fink M, Rossi M, Ai-Kateb H, O'Connell T, Hantash FM, Oh WK, Newman S, Schadt EE, Chen R, Hirsch FR. PMID: 35298662; PMCID: PMC9177106.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    16. Phase II Clinical and Translational Study of Everolimus ± Paclitaxel as First-Line Therapy in Cisplatin-Ineligible Advanced Urothelial Carcinoma. Oncologist. 2022 06 08; 27(6):432-e452. Jun T, Hahn NM, Sonpavde G, Albany C, MacVicar GR, Hauke R, Fleming M, Gourdin T, Jana B, Oh WK, Taik P, Wang H, Varadarajan AR, Uzilov A, Galsky MD. PMID: 35438782; PMCID: PMC9177111.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    17. Extraction of Treatment Information From Electronic Health Records and Evaluation of Testosterone Recovery in Patients With Prostate Cancer. JCO Clin Cancer Inform. 2022 06; 6:e2200010. Guin S, Jun T, Patel VG, Ayers KL, Deitz M, Cai Y, Zhou X, Tsao CK, Oh WK, Chen R, Liaw BC. PMID: 35696627; PMCID: PMC9225507.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    18. The effects of betamethasone on the amplitude integrated EEG of infants born at 34- or 35-weeks gestation. J Perinatol. 2022 12; 42(12):1615-1621. Laptook AR, Chalak L, Pappas A, Davis A, Sanchez PJ, Van Meurs KP, Oh W, Sommers R, Shankaran S, Hensman AM, Rouse DJ, McDonald S, Das A, Goldberg RN, Ambalavanan N, Gyamfi-Bannerman C, Thom EA, Higgins RD, Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Ne, Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medic. PMID: 35618748; PMCID: PMC9699898.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    19. The Impact of Androgen Deprivation Therapy on COVID-19 Illness in Men With Prostate Cancer. JNCI Cancer Spectr. 2022 05 02; 6(3). Shah NJ, Patel VG, Zhong X, Pina L, Hawley JE, Lin E, Gartrell BA, Febles VA, Wise DR, Qin Q, Mellgard G, Joshi H, Nauseef JT, Green DA, Vlachostergios PJ, Kwon DH, Huang F, Liaw B, Tagawa S, Kantoff P, Morris MJ, Oh WK. PMID: 35657341; PMCID: PMC9165550.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    20. Factors that guide selection among androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer. Clin Adv Hematol Oncol. 2022 May; 20 Suppl 9(5):1-20. Rettig MB, Beltran H, Oh WK. PMID: 35579577.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    21. Clinical observations regarding the use of androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer. Clin Adv Hematol Oncol. 2022 05; 20 Suppl 9(5):13-16. Oh WK. PMID: 35579580.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    22. Factors that guide selection among androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer: Q&A. Clin Adv Hematol Oncol. 2022 05; 20 Suppl 9(5):16-17. Oh WK, Rettig MB. PMID: 35579581.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    23. Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. Eur Urol. 2022 07; 82(1):115-141. Gillessen S, Armstrong A, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Bulbul M, Caffo O, Chi KN, Clarke CS, Clarke N, Davis ID, de Bono JS, Duran I, Eeles R, Efstathiou E, Efstathiou J, Ekeke ON, Evans CP, Fanti S, Feng FY, Fizazi K, Frydenberg M, George D, Gleave M, Halabi S, Heinrich D, Higano C, Hofman MS, Hussain M, James N, Jones R, Kanesvaran R, Khauli RB, Klotz L, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans AK, Morris MJ, Mottet N, Mrabti H, Murphy DG, Murthy V, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin M, Ryan CJ, Saad F, Sade JP, Sartor O, Scher HI, Shore N, Skoneczna I, Small E, Smith M, Soule H, Spratt DE, Sternberg CN, Suzuki H, Sweeney C, Sydes MR, Taplin ME, Tilki D, Tombal B, Türkeri L, Uemura H, Uemura H, van Oort I, Yamoah K, Ye D, Zapatero A, Omlin A. PMID: 35450732.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    24. Corrigendum to "What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021" [Eur Urol 82(1):6-11]. Eur Urol. 2022 Jul; 82(1):e18-e19. Turco F, Armstrong A, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Bulbul M, Caffo O, Chi KN, Clarke C, Clarke N, Davis ID, de Bono J, Duran I, Eeles R, Efstathiou E, Efstathiou J, Evans CP, Fanti S, Feng FY, Fizazi K, Frydenberg M, George D, Gleave M, Halabi S, Heinrich D, Higano C, Hofman MS, Hussain M, James N, Jones R, Kanesvaran R, Khauli RB, Klotz L, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans AK, Morris MJ, Mottet N, Mrabti H, Murphy DG, Murthy V, Oh WK, Ekeke ON, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin M, Ryan CJ, Saad F, Sade JP, Sartor O, Scher HI, Shore N, Skoneczna I, Small E, Smith M, Soule H, Spratt D, Sternberg CN, Suzuki H, Sweeney C, Sydes M, Taplin ME, Tilki D, Tombal B, Türkeri L, Uemura H, Uemura H, van Oort I, Yamoah K, Ye D, Zapatero A, Gillessen S, Omlin A. PMID: 35440417; PMCID: PMC9012951.
      View in: PubMed   Mentions:    Fields:    
    25. Inpatient Administration of Alpha-1-Adrenergic Receptor Blocking Agents Reduces Mortality in Male COVID-19 Patients. Front Med (Lausanne). 2022; 9:849222. Li S, Jun T, Tyler J, Schadt E, Kao YH, Wang Z, Konig MF, Bettegowda C, Vogelstein JT, Papadopoulos N, Parsons RE, Chen R, Schadt EE, Li L, Oh WK. PMID: 35295598; PMCID: PMC8919772.
      View in: PubMed   Mentions: 1  
    26. Reply to Carlos G. Wambier and Gerard J. Nau's Letter to the Editor re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285-93. Positive Effects of Enzalutamide for Hospitalized COVID-19 Patients: Still No Positive Effect of Enzalutamide for Hospitalized COVID-19 Patients. Eur Urol. 2022 Jun; 81(6):e143-e144. Welén K, Rosendal E, Freyhult E, Oh WK, Gisslén M, Ahlm C, Connolly AF, Överby AK, Josefsson A. PMID: 35248411; PMCID: PMC8864103.
      View in: PubMed   Mentions:    Fields:    Translation:CTClinical Trials
    27. What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021. Eur Urol. 2022 07; 82(1):6-11. Turco F, Armstrong A, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Bulbul M, Caffo O, Chi KN, Clarke C, Clarke N, Davis ID, de Bono J, Duran I, Eeles R, Efstathiou E, Efstathiou J, Evans CP, Fanti S, Feng FY, Fizazi K, Frydenberg M, George D, Gleave M, Halabi S, Heinrich D, Higano C, Hofman MS, Hussain M, James N, Jones R, Kanesvaran R, Khauli RB, Klotz L, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans AK, Morris MJ, Mottet N, Mrabti H, Murphy DG, Murthy V, Oh WK, Ekeke Onyeanunam N, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin M, Ryan CJ, Saad F, Pablo Sade J, Sartor O, Scher HI, Shore N, Skoneczna I, Small E, Smith M, Soule H, Spratt D, Sternberg CN, Suzuki H, Sweeney C, Sydes M, Taplin ME, Tilki D, Tombal B, Türkeri L, Uemura H, Uemura H, van Oort I, Yamoah K, Ye D, Zapatero A, Gillessen S, Omlin A. PMID: 35393158; PMCID: PMC8849852.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansPHPublic Health
    28. Impact of body mass index on the efficacy of aromatase inhibitors in patients with metastatic breast cancer. Breast Cancer Res Treat. 2022 Apr; 192(2):313-319. Patel R, Li Z, Zimmerman BS, Fink MY, Wells JD, Zhou X, Ayers K, Redfern A, Newman S, Schadt E, Oh WK, Chen R, Tiersten A. PMID: 35006484.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    29. Evolving Patterns of Metastasis in Renal Cell Carcinoma: Do We Need to Perform Routine Bone Imaging? J Kidney Cancer VHL. 2021; 8(4):13-19. Lin J, Zhang Y, Hou W, Qin Q, Galsky MD, Oh WK, Tsao CK. PMID: 34722126; PMCID: PMC8523177.
      View in: PubMed   Mentions: 1  
    30. A Rapid Guidance Process for the Development of an Anticoagulation Protocol in the COVID-19 Pandemic. Qual Manag Health Care. 2021 Oct-Dec 01; 30(4):276-279. Tremblay D, Dunn AS, Oh WK. PMID: 34048378; PMCID: PMC8462300.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCellsPHPublic Health
    31. The Evolving Clinical Management of Genitourinary Cancers Amid the COVID-19 Pandemic. Front Oncol. 2021; 11:734963. Izadmehr S, Lundon DJ, Mohamed N, Katims A, Patel V, Eilender B, Mehrazin R, Badani KK, Sfakianos JP, Tsao CK, Wiklund P, Oh WK, Cordon-Cardo C, Tewari AK, Galsky MD, Kyprianou N. PMID: 34646777; PMCID: PMC8504458.
      View in: PubMed   Mentions:
    32. Fluid Intake in the First Week of Life and the Duration of Hemodynamically Significant Patent Ductus Arteriosus in Extremely Preterm Infants. Am J Perinatol. 2023 09; 40(12):1345-1350. Mirza H, Garcia J, Bell C, Jones K, Flynn V, Pepe J, Oh W. PMID: 34384119.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    33. PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer. Prostate Cancer Prostatic Dis. 2022 09; 25(3):388-396. Koshkin VS, Patel VG, Ali A, Bilen MA, Ravindranathan D, Park JJ, Kellezi O, Cieslik M, Shaya J, Cabal A, Brown L, Labriola M, Graham LS, Pritchard C, Tripathi A, Nusrat S, Barata P, Jang A, Chen SR, Garje R, Acharya L, Hwang C, Pilling A, Oh W, Jun T, Natesan D, Nguyen C, Kilari D, Pierro M, Thapa B, Cackowski F, Mack A, Heath E, Marshall CH, Tagawa ST, Halabi S, Schweizer MT, Armstrong A, Dorff T, Alva A, McKay R. PMID: 34363009; PMCID: PMC9385488.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    34. Prostate Cancer Dormancy and Reactivation in Bone Marrow. J Clin Med. 2021 Jun 16; 10(12). Singh DK, Patel VG, Oh WK, Aguirre-Ghiso JA. PMID: 34208521; PMCID: PMC8234151.
      View in: PubMed   Mentions: 6  
    35. Analysis of Real-World Data to Investigate the Impact of Race and Ethnicity on Response to Programmed Cell Death-1 and Programmed Cell Death-Ligand 1 Inhibitors in Advanced Non-Small Cell Lung Cancers. Oncologist. 2021 07; 26(7):e1226-e1239. Ayers KL, Mullaney T, Zhou X, Liu JJ, Lee K, Ma M, Jones S, Li L, Redfern A, Jappe W, Liu Z, Goldsweig H, Yadav KK, Hahner N, Dietz M, Zimmerman M, Prentice T, Newman S, Veluswamy R, Wisnivesky J, Hirsch FR, Oh WK, Li SD, Schadt EE, Chen R. PMID: 33829580; PMCID: PMC8265370.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    36. Characterizing Prostate-Specific Antigen Levels at Death in Patients with Metastatic Castration-Resistant Prostate Cancer: Are We Underutilizing Imaging? Clin Genitourin Cancer. 2021 12; 19(6):e346-e351. Bikkasani K, Qin Q, Zhong X, Lin J, Galsky MD, Oh WK, Tsao CK. PMID: 34011488.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    37. Myeloid Cell-associated Resistance to PD-1/PD-L1 Blockade in Urothelial Cancer Revealed Through Bulk and Single-cell RNA Sequencing. Clin Cancer Res. 2021 08 01; 27(15):4287-4300. Wang L, Sfakianos JP, Beaumont KG, Akturk G, Horowitz A, Sebra RP, Farkas AM, Gnjatic S, Hake A, Izadmehr S, Wiklund P, Oh WK, Szabo PM, Wind-Rotolo M, Unsal-Kacmaz K, Yao X, Schadt E, Sharma P, Bhardwaj N, Zhu J, Galsky MD. PMID: 33837006; PMCID: PMC8338756.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCells
    38. Neurodevelopmental outcome of preterm infants enrolled in myo-inositol randomized controlled trial. J Perinatol. 2021 08; 41(8):2072-2087. Adams-Chapman I, Watterberg KL, Nolen TL, Hirsch S, Cole CA, Cotten CM, Oh W, Poindexter BB, Zaterka-Baxter KM, Das A, Lacy CB, Scorsone AM, Duncan AF, DeMauro SB, Goldstein RF, Colaizy TT, Wilson-Costello DE, Purdy IB, Hintz SR, Heyne RJ, Myers GJ, Fuller J, Merhar S, Harmon HM, Peralta-Carcelen M, Kilbride HW, Maitre NL, Vohr BR, Natarajan G, Mintz-Hittner H, Quinn GE, Wallace DK, Olson RJ, Orge FH, Tsui I, Gaynon M, Hutchinson AK, He YG, Winter TW, Yang MB, Haider KM, Cogen MS, Hug D, Bremer DL, Donahue JP, Lucas WR, Phelps DL, Higgins RD, Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Ne. PMID: 33758387; PMCID: PMC8349854.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    39. Risk Factors for Emergency Room and Hospital Care Among Patients With Solid Tumors on Immune Checkpoint Inhibitor Therapy. Am J Clin Oncol. 2021 03 01; 44(3):114-120. Parikh AB, Zhong X, Mellgard G, Qin Q, Patel VG, Wang B, Alerasool P, Garcia P, Leiter A, Gallagher EJ, Clinton S, Mortazavi A, Monk P, Folefac E, Yin M, Yang Y, Galsky M, Oh WK, Tsao CK. PMID: 33417323; PMCID: PMC7902456.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    40. Predicting toxicity-related docetaxel discontinuation and overall survival in metastatic castration-resistant prostate cancer: a pooled analysis of open phase 3 clinical trial data. Prostate Cancer Prostatic Dis. 2021 09; 24(3):743-749. Martini A, Parikh AB, Sfakianos JP, Montorsi F, Galsky MD, Oh WK, Tsao CK. PMID: 33531652.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    41. Accelerating precision medicine in metastatic prostate cancer. Nat Cancer. 2020 11; 1(11):1041-1053. Mateo J, McKay R, Abida W, Aggarwal R, Alumkal J, Alva A, Feng F, Gao X, Graff J, Hussain M, Karzai F, Montgomery B, Oh W, Patel V, Rathkopf D, Rettig M, Schultz N, Smith M, Solit D, Sternberg C, Van Allen E, VanderWeele D, Vinson J, Soule HR, Chinnaiyan A, Small E, Simons JW, Dahut W, Miyahira AK, Beltran H. PMID: 34258585; PMCID: PMC8274325.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    42. Hospitalised COVID-19 patients of the Mount Sinai Health System: a retrospective observational study using the electronic medical records. BMJ Open. 2020 10 26; 10(10):e040441. Wang Z, Zheutlin A, Kao YH, Ayers K, Gross S, Kovatch P, Nirenberg S, Charney A, Nadkarni G, De Freitas JK, O'Reilly P, Just A, Horowitz C, Martin G, Branch A, Glicksberg BS, Charney D, Reich D, Oh WK, Schadt E, Chen R, Li L. PMID: 33109676; PMCID: PMC7592304.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCellsPHPublic Health
    43. Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations. JAMA Netw Open. 2020 10 01; 3(10):e2021692. Schmid S, Omlin A, Higano C, Sweeney C, Martinez Chanza N, Mehra N, Kuppen MCP, Beltran H, Conteduca V, Vargas Pivato de Almeida D, Cotait Maluf F, Oh WK, Tsao CK, Sartor O, Ledet E, Di Lorenzo G, Yip SM, Chi KN, Bianchini D, De Giorgi U, Hansen AR, Beer TM, Lavaud P, Morales-Barrera R, Tucci M, Castro E, Karalis K, Bergman AM, Le ML, Zürrer-Härdi U, Pezaro C, Suzuki H, Zivi A, Klingbiel D, Schär S, Gillessen S. PMID: 33112397; PMCID: PMC7593810.
      View in: PubMed   Mentions: 42     Fields:    Translation:Humans
    44. Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART II. J Urol. 2021 Jan; 205(1):22-29. Lowrance WT, Breau RH, Chou R, Chapin BF, Crispino T, Dreicer R, Jarrard DF, Kibel AS, Morgan TM, Morgans AK, Oh WK, Resnick MJ, Zietman AL, Cookson MS. PMID: 32960678.
      View in: PubMed   Mentions: 47     Fields:    Translation:Humans
    45. Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I. J Urol. 2021 Jan; 205(1):14-21. Lowrance WT, Breau RH, Chou R, Chapin BF, Crispino T, Dreicer R, Jarrard DF, Kibel AS, Morgan TM, Morgans AK, Oh WK, Resnick MJ, Zietman AL, Cookson MS. PMID: 32960679.
      View in: PubMed   Mentions: 76     Fields:    Translation:Humans
    46. Blood myo-inositol concentrations in preterm and term infants. J Perinatol. 2021 02; 41(2):247-254. Brion LP, Phelps DL, Ward RM, Nolen TL, Hallman NMK, Das A, Zaccaro DJ, Ball MB, Watterberg KL, Frantz ID, Cotten CM, Poindexter BB, Oh W, Lugo RA, Van Meurs KP, O'Shea TM, Zaterka-Baxter KM, Higgins RD, Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Ne. PMID: 32934363; PMCID: PMC7889639.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    47. Treatment of muscle-invasive and advanced bladder cancer in 2020. CA Cancer J Clin. 2020 09; 70(5):404-423. Patel VG, Oh WK, Galsky MD. PMID: 32767764.
      View in: PubMed   Mentions: 339     Fields:    Translation:Humans
    48. Lacrimal sac adenocarcinoma managed with androgen deprivation. Am J Ophthalmol Case Rep. 2020 Sep; 19:100607. Abramson DH, Fallon J, Biran N, Francis JH, Jaben K, Oh WK. PMID: 32760849; PMCID: PMC7393461.
      View in: PubMed   Mentions:
    49. Impact of anticoagulation prior to COVID-19 infection: a propensity score-matched cohort study. Blood. 2020 Jul 02; 136(1):144-147. Tremblay D, van Gerwen M, Alsen M, Thibaud S, Kessler A, Venugopal S, Makki I, Qin Q, Dharmapuri S, Jun T, Bhalla S, Berwick S, Feld J, Mascarenhas J, Troy K, Cromwell C, Dunn A, Oh WK, Naymagon L. PMID: 32462179; PMCID: PMC7332896.
      View in: PubMed   Mentions: 92     Fields:    Translation:HumansCellsPHPublic Health
    50. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. Eur Urol. 2020 04; 77(4):508-547. Gillessen S, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Chi KN, Clarke N, Davis ID, de Bono J, Drake CG, Duran I, Eeles R, Efstathiou E, Evans CP, Fanti S, Feng FY, Fizazi K, Frydenberg M, Gleave M, Halabi S, Heidenreich A, Heinrich D, Higano CTS, Hofman MS, Hussain M, James N, Kanesvaran R, Kantoff P, Khauli RB, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans AK, Morris MJ, Mottet N, Mrabti H, Murphy DG, Murthy V, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Reiter RE, Roach M, Rubin M, Ryan CJ, Saad F, Sade JP, Sartor O, Scher HI, Shore N, Small E, Smith M, Soule H, Sternberg CN, Steuber T, Suzuki H, Sweeney C, Sydes MR, Taplin ME, Tombal B, Türkeri L, van Oort I, Zapatero A, Omlin A. PMID: 32001144.
      View in: PubMed   Mentions: 139     Fields:    Translation:Humans
    51. Tracheomegaly among Extremely Preterm Infants on Prolonged Mechanical Ventilation. J Pediatr. 2020 03; 218:231-233.e1. Mirza H, Varich L, Sensakovic WF, Guruvadoo K, Royall I, Britt C, Vicenti R, Oh W. PMID: 31711760.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    52. Duration of significant patent ductus arteriosus and bronchopulmonary dysplasia in extremely preterm infants. J Perinatol. 2019 12; 39(12):1648-1655. Mirza H, Garcia J, McKinley G, Hubbard L, Sensing W, Schneider J, Oh W, Wadhawan R. PMID: 31554913.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    53. Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer. Eur Urol. 2019 11; 76(5):599-603. Wang L, Gong Y, Saci A, Szabo PM, Martini A, Necchi A, Siefker-Radtke A, Pal S, Plimack ER, Sfakianos JP, Bhardwaj N, Horowitz A, Farkas AM, Mulholland D, Fischer BS, Oh WK, Sharma P, Zhu J, Galsky MD. PMID: 31272788; PMCID: PMC6801024.
      View in: PubMed   Mentions: 48     Fields:    Translation:HumansCells
    54. Prostate Cancer in World Trade Center Responders Demonstrates Evidence of an Inflammatory Cascade. Mol Cancer Res. 2019 08; 17(8):1605-1612. Gong Y, Wang L, Yu H, Alpert N, Cohen MD, Prophete C, Horton L, Sisco M, Park SH, Lee HW, Zelikoff J, Chen LC, Hashim D, Suarez-Farinas M, Donovan MJ, Aaronson SA, Galsky M, Zhu J, Taioli E, Oh WK. PMID: 31221798; PMCID: PMC6684261.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    55. Programmed Death-1 or Programmed Death Ligand-1 Blockade in Patients with Platinum-resistant Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis. Eur Urol. 2019 Dec; 76(6):782-789. Niglio SA, Jia R, Ji J, Ruder S, Patel VG, Martini A, Sfakianos JP, Marqueen KE, Waingankar N, Mehrazin R, Wiklund P, Oh WK, Mazumdar M, Ferket BS, Galsky MD. PMID: 31200951.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    56. The evolving landscape of immunotherapy in advanced prostate cancer. Immunotherapy. 2019 07; 11(10):903-912. Patel VG, Oh WK. PMID: 31161846.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    57. Effects of Myo-inositol on Type 1 Retinopathy of Prematurity Among Preterm Infants <28 Weeks' Gestational Age: A Randomized Clinical Trial. JAMA. 2018 10 23; 320(16):1649-1658. Phelps DL, Watterberg KL, Nolen TL, Cole CA, Cotten CM, Oh W, Poindexter BB, Zaterka-Baxter KM, Das A, Lacy CB, Scorsone AM, Walsh MC, Bell EF, Kennedy KA, Schibler K, Sokol GM, Laughon MM, Lakshminrusimha S, Truog WE, Garg M, Carlo WA, Laptook AR, Van Meurs KP, Carlton DP, Graf A, DeMauro SB, Brion LP, Shankaran S, Orge FH, Olson RJ, Mintz-Hittner H, Yang MB, Haider KM, Wallace DK, Chung M, Hug D, Tsui I, Cogen MS, Donahue JP, Gaynon M, Hutchinson AK, Bremer DL, Quinn G, He YG, Lucas WR, Winter TW, Kicklighter SD, Kumar K, Chess PR, Colaizy TT, Hibbs AM, Ambalavanan N, Harmon HM, McGowan EC, Higgins RD, Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Ne. PMID: 30357297; PMCID: PMC6233812.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    58. The role of ketoconazole in current prostate cancer care. Nat Rev Urol. 2018 10; 15(10):643-651. Patel V, Liaw B, Oh W. PMID: 30154429.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    59. Multimodal therapy in the treatment of metastatic prostate cancer: A case report. Urol Case Rep. 2018 Nov; 21:92-94. Omidele OO, Schiff HI, Oh W, Tewari A. PMID: 30258788; PMCID: PMC6154777.
      View in: PubMed   Mentions:
    60. A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab. J Immunother Cancer. 2018 09 18; 6(1):90. Friedlander P, Wood K, Wassmann K, Christenfeld AM, Bhardwaj N, Oh WK. PMID: 30227886; PMCID: PMC6145108.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    61. Real World Experience of Drug Induced Liver Injury in Patients Undergoing Chemotherapy. J Clin Gastroenterol Hepatol. 2018; 2(3). Azad A, Chang P, Devuni D, Bichoupan K, Kesar V, Branch AD, Oh WK, Galsky MD, Ahmad J, Odin JA. PMID: 30637414; PMCID: PMC6327955.
      View in: PubMed   Mentions: 2  
    62. Real-world outcomes in patients with metastatic castration-resistant prostate cancer receiving second-line chemotherapy versus an alternative androgen receptor-targeted agent (ARTA) following early progression on a first-line ARTA in a US community oncology setting. Urol Oncol. 2018 11; 36(11):500.e1-500.e9. Oh WK, Cheng WY, Miao R, Vekeman F, Gauthier-Loiselle M, Duh MS, Drea E, Szatrowski TP. PMID: 30201382.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    63. EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer. Nat Commun. 2018 08 29; 9(1):3503. Wang L, Saci A, Szabo PM, Chasalow SD, Castillo-Martin M, Domingo-Domenech J, Siefker-Radtke A, Sharma P, Sfakianos JP, Gong Y, Dominguez-Andres A, Oh WK, Mulholland D, Azrilevich A, Hu L, Cordon-Cardo C, Salmon H, Bhardwaj N, Zhu J, Galsky MD. PMID: 30158554; PMCID: PMC6115401.
      View in: PubMed   Mentions: 138     Fields:    Translation:HumansAnimals
    64. Castration-Resistant Prostate Cancer: AUA Guideline Amendment 2018. J Urol. 2018 12; 200(6):1264-1272. Lowrance WT, Murad MH, Oh WK, Jarrard DF, Resnick MJ, Cookson MS. PMID: 30086276.
      View in: PubMed   Mentions: 52     Fields:    Translation:Humans
    65. Prostate-specific antigen doubling time is a significant predictor of overall and disease-free survival in patients with prostate adenocarcinoma treated with brachytherapy. Brachytherapy. 2018 Nov - Dec; 17(6):874-881. Resende Salgado L, Rhome R, Oh W, Stone N, Stock R. PMID: 30061057.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    66. Identification of microR-106b as a prognostic biomarker of p53-like bladder cancers by ActMiR. Oncogene. 2018 11; 37(44):5858-5872. Lee E, Collazo-Lorduy A, Castillo-Martin M, Gong Y, Wang L, Oh WK, Galsky MD, Cordon-Cardo C, Zhu J. PMID: 29970902; PMCID: PMC6212417.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    67. Prostate cancer characteristics in the World Trade Center cohort, 2002-2013. Eur J Cancer Prev. 2018 07; 27(4):347-354. Hashim D, Boffetta P, Galsky M, Oh W, Lucchini R, Crane M, Luft B, Moline J, Udasin I, Harrison D, Taioli E. PMID: 27898584; PMCID: PMC5443704.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansPHPublic Health
    68. Effects of soybean lipid infusion on triglyceride and unbound free fatty acid levels in preterm infants. J Matern Fetal Neonatal Med. 2019 Oct; 32(19):3226-3231. Hegyi T, Kleinfeld A, Huber A, Weinberger B, Memon N, Joe Shih W, Carayannopoulos M, Oh W. PMID: 29618229; PMCID: PMC6551293.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    69. Profile of apalutamide in the treatment of metastatic castration-resistant prostate cancer: evidence to date. Onco Targets Ther. 2018; 11:2141-2147. Chong JT, Oh WK, Liaw BC. PMID: 29695920; PMCID: PMC5905496.
      View in: PubMed   Mentions: 17  
    70. Natural History of Postnatal Cardiopulmonary Adaptation in Infants Born Extremely Preterm and Risk for Death or Bronchopulmonary Dysplasia. J Pediatr. 2018 07; 198:187-193.e1. Mirza H, Garcia JA, Crawford E, Pepe J, Zussman M, Wadhawan R, Oh W. PMID: 29625730.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    71. Unbound bilirubin measurements by a novel probe in preterm infants. J Matern Fetal Neonatal Med. 2019 Aug; 32(16):2721-2726. Hegyi T, Kleinfeld A, Huber A, Weinberger B, Memon N, Shih W, Carayannopoulos M, Oh W. PMID: 29504491; PMCID: PMC6135709.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    72. First-Line Treatment of Hormone-Sensitive Metastatic Prostate Cancer: Is There a Single Standard of Care? J Clin Oncol. 2018 04 10; 36(11):1060-1061. Tsao CK, Oh WK. PMID: 29432079.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    73. Small-Molecule Activators of Protein Phosphatase 2A for the Treatment of Castration-Resistant Prostate Cancer. Cancer Res. 2018 04 15; 78(8):2065-2080. McClinch K, Avelar RA, Callejas D, Izadmehr S, Wiredja D, Perl A, Sangodkar J, Kastrinsky DB, Schlatzer D, Cooper M, Kiselar J, Stachnik A, Yao S, Hoon D, McQuaid D, Zaware N, Gong Y, Brautigan DL, Plymate SR, Sprenger CCT, Oh WK, Levine AC, Kirschenbaum A, Sfakianos JP, Sears R, DiFeo A, Ioannou Y, Ohlmeyer M, Narla G, Galsky MD. PMID: 29358171; PMCID: PMC5899650.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansAnimalsCells
    74. Association of intralipid intake in extremely low birthweight infants with neurodevelopmental outcomes. Acta Paediatr. 2018 Apr; 107(4):600-604. Oh W, Przystac L, McKinley L, Tucker R, McGowan EC, Vohr BR. PMID: 29274180.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    75. Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes. Eur Urol. 2018 05; 73(5):751-759. Galsky MD, Wang H, Hahn NM, Twardowski P, Pal SK, Albany C, Fleming MT, Starodub A, Hauke RJ, Yu M, Zhao Q, Sonpavde G, Donovan MJ, Patel VG, Sfakianos JP, Domingo-Domenech J, Oh WK, Akers N, Losic B, Gnjatic S, Schadt EE, Chen R, Kim-Schulze S, Bhardwaj N, Uzilov AV. PMID: 29248319.
      View in: PubMed   Mentions: 55     Fields:    Translation:HumansCTClinical Trials
    76. Racial Disparities in Clinically Significant Prostate Cancer Treatment: The Potential Health Information Technology Offers. J Oncol Pract. 2018 01; 14(1):e23-e33. Bickell NA, Lin JJ, Abramson SR, Hoke GP, Oh W, Hall SJ, Stock R, Fei K, McAlearney AS. PMID: 29194001; PMCID: PMC5765902.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    77. Hospital Centralization Impacts High-Risk Lung and Bladder Cancer Surgical Patients. Cancer Invest. 2017 Nov 26; 35(10):652-661. Lieberman-Cribbin W, Galsky M, Casey M, Liu B, Oh W, Flores R, Taioli E. PMID: 29243986.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    78. Telemedicine-Enabled Clinical Trial of Metformin in Patients With Prostate Cancer. JCO Clin Cancer Inform. 2017 11; 1:1-10. Galsky MD, Shahin M, Jia R, Shaffer DR, Gimpel-Tetra K, Tsao CK, Baker C, Leiter A, Holland J, Sablinski T, Mehrazin R, Sfakianos JP, Acon P, Oh WK. PMID: 30657386.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    79. Web-Based Tool to Facilitate Shared Decision Making With Regard to Neoadjuvant Chemotherapy Use in Muscle-Invasive Bladder Cancer. JCO Clin Cancer Inform. 2017 11; 1:1-12. Galsky MD, Diefenbach M, Mohamed N, Baker C, Pokhriya S, Rogers J, Atreja A, Hu L, Tsao CK, Sfakianos J, Mehrazin R, Waingankar N, Oh WK, Mazumdar M, Ferket BS. PMID: 30657403; PMCID: PMC6874030.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    80. Recognizing Symptom Burden in Advanced Prostate Cancer: A Global Patient and Caregiver Survey. Clin Genitourin Cancer. 2018 04; 16(2):e411-e419. Drudge-Coates L, Oh WK, Tombal B, Delacruz A, Tomlinson B, Ripley AV, Mastris K, O'Sullivan JM, Shore ND. PMID: 29111175.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    81. Whole-blood RNA transcript-based models can predict clinical response in two large independent clinical studies of patients with advanced melanoma treated with the checkpoint inhibitor, tremelimumab. J Immunother Cancer. 2017 08 15; 5(1):67. Friedlander P, Wassmann K, Christenfeld AM, Fisher D, Kyi C, Kirkwood JM, Bhardwaj N, Oh WK. PMID: 28807052; PMCID: PMC5557000.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    82. Patient characteristics and overall survival in patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting. Med Oncol. 2017 Aug 10; 34(9):160. Oh WK, Miao R, Vekeman F, Sung J, Cheng WY, Gauthier-Loiselle M, Dhawan R, Duh MS. PMID: 28795333; PMCID: PMC5550521.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    83. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol. 2018 02; 73(2):178-211. Gillessen S, Attard G, Beer TM, Beltran H, Bossi A, Bristow R, Carver B, Castellano D, Chung BH, Clarke N, Daugaard G, Davis ID, de Bono J, Borges Dos Reis R, Drake CG, Eeles R, Efstathiou E, Evans CP, Fanti S, Feng F, Fizazi K, Frydenberg M, Gleave M, Halabi S, Heidenreich A, Higano CS, James N, Kantoff P, Kellokumpu-Lehtinen PL, Khauli RB, Kramer G, Logothetis C, Maluf F, Morgans AK, Morris MJ, Mottet N, Murthy V, Oh W, Ost P, Padhani AR, Parker C, Pritchard CC, Roach M, Rubin MA, Ryan C, Saad F, Sartor O, Scher H, Sella A, Shore N, Smith M, Soule H, Sternberg CN, Suzuki H, Sweeney C, Sydes MR, Tannock I, Tombal B, Valdagni R, Wiegel T, Omlin A. PMID: 28655541.
      View in: PubMed   Mentions: 184     Fields:    Translation:Humans
    84. Real-world Characteristics and Outcomes of Patients With Metastatic Castration-resistant Prostate Cancer Receiving Chemotherapy Versus Androgen Receptor-targeted Therapy After Failure of First-line Androgen Receptor-targeted Therapy in the Community Setting. Clin Genitourin Cancer. 2017 Jun 19. Oh WK, Miao R, Vekeman F, Sung J, Cheng WY, Gauthier-Loiselle M, Dhawan R, Duh MS. PMID: 28729067.
      View in: PubMed   Mentions: 10     Fields:    
    85. The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer. Cancer. 2017 Sep 15; 123(18):3532-3539. Pomerantz MM, Spisák S, Jia L, Cronin AM, Csabai I, Ledet E, Sartor AO, Rainville I, O'Connor EP, Herbert ZT, Szállási Z, Oh WK, Kantoff PW, Garber JE, Schrag D, Kibel AS, Freedman ML. PMID: 28608931; PMCID: PMC5802871.
      View in: PubMed   Mentions: 113     Fields:    Translation:Humans
    86. Moving beyond vascular endothelial growth factor-targeted therapy in renal cell cancer: latest evidence and therapeutic implications. Ther Adv Med Oncol. 2017 Apr; 9(4):287-298. Tsao CK, Liaw B, He C, Galsky MD, Sfakianos J, Oh WK. PMID: 28491148; PMCID: PMC5405995.
      View in: PubMed   Mentions: 3  
    87. Effects of Soybean Lipid Infusion on Unbound Free Fatty Acids and Unbound Bilirubin in Preterm Infants. J Pediatr. 2017 05; 184:45-50.e1. Hegyi T, Kleinfeld A, Huber A, Weinberger B, Memon N, Shih WJ, Carayannopoulos M, Oh W. PMID: 28108102; PMCID: PMC5403563.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    88. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma. J Immunother Cancer. 2016; 4:92. McNeel DG, Bander NH, Beer TM, Drake CG, Fong L, Harrelson S, Kantoff PW, Madan RA, Oh WK, Peace DJ, Petrylak DP, Porterfield H, Sartor O, Shore ND, Slovin SF, Stein MN, Vieweg J, Gulley JL. PMID: 28031820; PMCID: PMC5170901.
      View in: PubMed   Mentions: 21     Fields:    
    89. Strategies to avoid treatment-induced lineage crisis in advanced prostate cancer. Nat Rev Clin Oncol. 2017 05; 14(5):269-283. Roubaud G, Liaw BC, Oh WK, Mulholland DJ. PMID: 27874061; PMCID: PMC5567685.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCells
    90. Constructing Bayesian networks by integrating gene expression and copy number data identifies NLGN4Y as a novel regulator of prostate cancer progression. Oncotarget. 2016 10 18; 7(42):68688-68707. Gong Y, Wang L, Chippada-Venkata U, Dai X, Oh WK, Zhu J. PMID: 27626693; PMCID: PMC5356583.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    91. Phase II Trial of Abiraterone Acetate Plus Prednisone in Black Men With Metastatic Prostate Cancer. Oncologist. 2016 12; 21(12):1414-e9. Tsao CK, Sfakianos J, Liaw B, Gimpel-Tetra K, Kemeny M, Bulone L, Shahin M, Oh WK, Galsky MD. PMID: 27742908; PMCID: PMC5153336.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    92. Disease-specific classification using deconvoluted whole blood gene expression. Sci Rep. 2016 09 06; 6:32976. Wang L, Oh WK, Zhu J. PMID: 27596246; PMCID: PMC5011717.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    93. The Relationship between Centralization of Care and Geographic Barriers to Cystectomy for Bladder Cancer. Bladder Cancer. 2016 Jul 27; 2(3):319-327. Casey MF, Wisnivesky J, Le VH, Sarpel U, Stensland KD, Oh WK, Galsky MD. PMID: 27500199; PMCID: PMC4969695.
      View in: PubMed   Mentions: 11  
    94. Obesity and Outcomes in Patients with Metastatic Urothelial Carcinoma. Bladder Cancer. 2016 Jul 27; 2(3):341-349. Leiter A, Doucette J, Krege S, Lin CC, Hahn N, Ecke T, Sonpavde G, Bamias A, Oh WK, Galsky MD. PMID: 27500201; PMCID: PMC4969712.
      View in: PubMed   Mentions: 4  
    95. Docetaxel for Metastatic Hormone-sensitive Prostate Cancer: Urgent Need to Minimize the Risk of Neutropenic Fever. Eur Urol. 2016 11; 70(5):707-708. Tsao CK, Galsky MD, Oh WK. PMID: 27417033.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    96. Comparative Effectiveness of Treatment Strategies for Bladder Cancer With Clinical Evidence of Regional Lymph Node Involvement. J Clin Oncol. 2016 08 01; 34(22):2627-35. Galsky MD, Stensland K, Sfakianos JP, Mehrazin R, Diefenbach M, Mohamed N, Tsao CK, Boffetta P, Wiklund P, Oh WK, Mazumdar M, Ferket B. PMID: 27269939; PMCID: PMC5012691.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    97. A 2-Gene Panel Derived From Prostate Cancer-Enhanced Transcripts in Whole Blood Is Prognostic for Survival and Predicts Treatment Benefit in Metastatic Castration-Resistant Prostate Cancer. Prostate. 2016 09; 76(13):1160-8. Heck MM, Thalgott M, Schmid SC, Oh WK, Gong Y, Wang L, Zhu J, Seitz AK, Porst D, Höppner M, Retz M, Gschwend JE, Nawroth R. PMID: 27198487.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    98. Urachal Carcinoma Shares Genomic Alterations with Colorectal Carcinoma and May Respond to Epidermal Growth Factor Inhibition. Eur Urol. 2016 11; 70(5):771-775. Collazo-Lorduy A, Castillo-Martin M, Wang L, Patel V, Iyer G, Jordan E, Al-Ahmadie H, Leonard I, Oh WK, Zhu J, McBride RB, Cordon-Cardo C, Solit DB, Sfakianos JP, Galsky MD. PMID: 27178450; PMCID: PMC5489411.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansCells
    99. Safety and pharmacokinetics of multiple dose myo-inositol in preterm infants. Pediatr Res. 2016 08; 80(2):209-17. Phelps DL, Ward RM, Williams RL, Nolen TL, Watterberg KL, Oh W, Goedecke M, Ehrenkranz RA, Fennell T, Poindexter BB, Cotten CM, Hallman M, Frantz ID, Faix RG, Zaterka-Baxter KM, Das A, Ball MB, Lacy CB, Walsh MC, Carlo WA, Sánchez PJ, Bell EF, Shankaran S, Carlton DP, Chess PR, Higgins RD. PMID: 27074126; PMCID: PMC5198845.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    100. Severe post-treatment leukopenia associated with the development of encephalopathy following ifosfamide infusion. Anticancer Drugs. 2016 Mar; 27(3):235-8. Kim SS, Isola LM, Oh WK. PMID: 26628483.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    101. Effectiveness of Adjuvant Chemotherapy for Locally Advanced Bladder Cancer. J Clin Oncol. 2016 Mar 10; 34(8):825-32. Galsky MD, Stensland KD, Moshier E, Sfakianos JP, McBride RB, Tsao CK, Casey M, Boffetta P, Oh WK, Mazumdar M, Wisnivesky JP. PMID: 26786930.
      View in: PubMed   Mentions: 59     Fields:    Translation:Humans
    102. Effects of indomethacin prophylaxis timing on intraventricular haemorrhage and patent ductus arteriosus in extremely low birth weight infants. Arch Dis Child Fetal Neonatal Ed. 2016 Sep; 101(5):F418-22. Mirza H, Laptook AR, Oh W, Vohr BR, Stoll BJ, Kandefer S, Stonestreet BS, Generic Database Subcommittee of the NICHD Neonatal Research Network. PMID: 26733540; PMCID: PMC4935651.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    103. Effects of Placental Transfusion on Neonatal and 18 Month Outcomes in Preterm Infants: A Randomized Controlled Trial. J Pediatr. 2016 Jan; 168:50-55.e1. Mercer JS, Erickson-Owens DA, Vohr BR, Tucker RJ, Parker AB, Oh W, Padbury JF. PMID: 26547399; PMCID: PMC4698069.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    104. Generation of Prostate Cancer Patient Derived Xenograft Models from Circulating Tumor Cells. J Vis Exp. 2015 Oct 20; (105):53182. Williams ES, Rodriguez-Bravo V, Rodriquez-Bravo V, Chippada-Venkata U, De Ia Iglesia-Vicente J, Gong Y, Galsky M, Oh W, Cordon-Cardo C, Domingo-Domenech J. PMID: 26555435; PMCID: PMC4692658.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansAnimalsCells
    105. Phase 2 trial of the topoisomerase II inhibitor, amrubicin, as second-line therapy in patients with metastatic urothelial carcinoma. Cancer Chemother Pharmacol. 2015 Dec; 76(6):1259-65. Galsky MD, Hahn NM, Wong B, Lee KM, Argiriadi P, Albany C, Gimpel-Tetra K, Lowe N, Shahin M, Patel V, Tsao CK, Oh WK. PMID: 26464352.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    106. A robust blood gene expression-based prognostic model for castration-resistant prostate cancer. BMC Med. 2015 Aug 21; 13:201. Wang L, Gong Y, Chippada-Venkata U, Heck MM, Retz M, Nawroth R, Galsky M, Tsao CK, Schadt E, de Bono J, Olmos D, Zhu J, Oh WK. PMID: 26297150; PMCID: PMC4546313.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    107. Concurrent Diabetes Mellitus may Negatively Influence Clinical Progression and Response to Androgen Deprivation Therapy in Patients with Advanced Prostate Cancer. Front Oncol. 2015; 5:129. Shevach J, Gallagher EJ, Kochukoshy T, Gresia V, Brar M, Galsky MD, Oh WK. PMID: 26125012; PMCID: PMC4467174.
      View in: PubMed   Mentions: 3  
    108. Urological cancer: Is docetaxel the 'black widow' of mCRPC drugs? Nat Rev Clin Oncol. 2015 Jun; 12(6):316-8. Liaw BC, Oh WK. PMID: 25917253.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    109. Systemic therapy for the treatment of hormone-sensitive metastatic prostate cancer: from intermittent androgen deprivation therapy to chemotherapy. Curr Urol Rep. 2015 Mar; 16(3):13. Liaw BC, Shevach J, Oh WK. PMID: 25677235.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    110. Clinical trial awareness: Changes over time and sociodemographic disparities. Clin Trials. 2015 Jun; 12(3):215-23. Leiter A, Diefenbach MA, Doucette J, Oh WK, Galsky MD. PMID: 25673636; PMCID: PMC4667750.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    111. Geographic accessibility to clinical trials for advanced cancer in the United States. JAMA Intern Med. 2015 Feb; 175(2):293-5. Galsky MD, Stensland KD, McBride RB, Latif A, Moshier E, Oh WK, Wisnivesky J. PMID: 25437434.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    112. Patients with Biopsy Gleason 9 and 10 Prostate Cancer Have Significantly Worse Outcomes Compared to Patients with Gleason 8 Disease. J Urol. 2015 Jul; 194(1):91-7. Tsao CK, Gray KP, Nakabayashi M, Evan C, Kantoff PW, Huang J, Galsky MD, Pomerantz M, Oh WK. PMID: 25623747.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    113. The Impact of Regionalization of Cystectomy on Racial Disparities in Bladder Cancer Care. J Urol. 2015 Jul; 194(1):36-41. Casey MF, Gross T, Wisnivesky J, Stensland KD, Oh WK, Galsky MD. PMID: 25623748.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    114. Elevated circulating tissue inhibitor of metalloproteinase 1 (TIMP-1) levels are associated with neuroendocrine differentiation in castration resistant prostate cancer. Prostate. 2015 May; 75(6):616-27. Gong Y, Chippada-Venkata UD, Galsky MD, Huang J, Oh WK. PMID: 25560638.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    115. Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate cancer. Invest New Drugs. 2015 Apr; 33(2):397-408. Petrylak DP, Gandhi JG, Clark WR, Heath E, Lin J, Oh WK, Agus DB, Carthon B, Moran S, Kong N, Suri A, Bargfrede M, Liu G. PMID: 25556680; PMCID: PMC4390470.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    116. Cytotoxic chemotherapy in the contemporary management of metastatic castration-resistant prostate cancer (mCRPC). BJU Int. 2015 Jul; 116(1):17-29. Sonpavde G, Wang CG, Galsky MD, Oh WK, Armstrong AJ. PMID: 25046451.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    117. A phase I study of everolimus and docetaxel in patients with castration-resistant prostate cancer. Clin Genitourin Cancer. 2015 Apr; 13(2):113-23. Courtney KD, Manola JB, Elfiky AA, Ross R, Oh WK, Yap JT, Van den Abbeele AD, Ryan CW, Beer TM, Loda M, Priolo C, Kantoff P, Taplin ME. PMID: 25450031; PMCID: PMC4418946.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    118. Use of crowdsourcing for cancer clinical trial development. J Natl Cancer Inst. 2014 Oct; 106(10). Leiter A, Sablinski T, Diefenbach M, Foster M, Greenberg A, Holland J, Oh WK, Galsky MD. PMID: 25217580.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    119. Adult cancer clinical trials that fail to complete: an epidemic? J Natl Cancer Inst. 2014 Sep; 106(9). Stensland KD, McBride RB, Latif A, Wisnivesky J, Hendricks R, Roper N, Boffetta P, Hall SJ, Oh WK, Galsky MD. PMID: 25190726.
      View in: PubMed   Mentions: 57     Fields:    Translation:Humans
    120. Phase Ib/II trial of gemcitabine, cisplatin, and lenalidomide as first-line therapy in patients with metastatic urothelial carcinoma. Oncologist. 2014 Sep; 19(9):915-6. Agarwal N, Apolo AB, Tsao CK, Lee KM, Godbold JH, Soto R, Poole A, Gimpel-Tetra K, Lowe N, Oh WK, Galsky MD. PMID: 25052451; PMCID: PMC4153455.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    121. Phase Ib study of dovitinib in combination with gemcitabine plus cisplatin or gemcitabine plus carboplatin in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Sep; 74(3):465-71. Galsky MD, Posner M, Holcombe RF, Lee KM, Misiukiewicz K, Tsao CK, Godbold J, Soto R, Gimpel-Tetra K, Lowe N, Oh WK. PMID: 25023489; PMCID: PMC4146643.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    122. Roles of matrix metalloproteinases and their natural inhibitors in prostate cancer progression. Cancers (Basel). 2014 Jun 27; 6(3):1298-327. Gong Y, Chippada-Venkata UD, Oh WK. PMID: 24978435; PMCID: PMC4190542.
      View in: PubMed   Mentions: 67  
    123. Mind the gap: efficacy versus effectiveness and pivotal prostate cancer clinical trial demographics. Cancer. 2014 Oct 01; 120(19):2944-5. Galsky MD, Oh WK. PMID: 24965362.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    124. The role of cabazitaxel in the treatment of metastatic castration-resistant prostate cancer. Ther Adv Urol. 2014 Jun; 6(3):97-104. Tsao CK, Cutting E, Martin J, Oh WK. PMID: 24883107; PMCID: PMC4003844.
      View in: PubMed   Mentions: 25  
    125. The metastatic castration-resistant prostate cancer treatment paradigm: more choices, more questions. Asian J Androl. 2014 May-Jun; 16(3):331-3. Yu EY, Oh WK. PMID: 24759585; PMCID: PMC4023355.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    126. Blood mRNA expression profiling predicts survival in patients treated with tremelimumab. Clin Cancer Res. 2014 Jun 15; 20(12):3310-8. Saenger Y, Magidson J, Liaw B, de Moll E, Harcharik S, Fu Y, Wassmann K, Fisher D, Kirkwood J, Oh WK, Friedlander P. PMID: 24721645.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    127. T2 muscle-invasive bladder cancer. Semin Oncol. 2014 Apr; 41(2):e11-8. Tsao CK, Small A, Hall S, Oh WK, Galsky MD, Buckstein M, Stock R, Ali G, Morris GJ. PMID: 24787300.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    128. Dissection of immune gene networks in primary melanoma tumors critical for antitumor surveillance of patients with stage II-III resectable disease. J Invest Dermatol. 2014 Aug; 134(8):2202-2211. Sivendran S, Chang R, Pham L, Phelps RG, Harcharik ST, Hall LD, Bernardo SG, Moskalenko MM, Sivendran M, Fu Y, de Moll EH, Pan M, Moon JY, Arora S, Cohain A, DiFeo A, Ferringer TC, Tismenetsky M, Tsui CL, Friedlander PA, Parides MK, Banchereau J, Chaussabel D, Lebwohl MG, Wolchok JD, Bhardwaj N, Burakoff SJ, Oh WK, Palucka K, Merad M, Schadt EE, Saenger YM. PMID: 24522433; PMCID: PMC4291112.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    129. Impact of prednisone on toxicities and survival in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis of randomized clinical trials. Crit Rev Oncol Hematol. 2014 Jun; 90(3):253-61. Morgan CJ, Oh WK, Naik G, Galsky MD, Sonpavde G. PMID: 24500033.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    130. Is metastatic prostate cancer changing, and how will we know it? It's time for standard nomenclature for nonosseous metastases in clinical trials of patients with metastatic castration resistant prostate cancer. Eur Urol. 2014 Aug; 66(2):184-5. Tsao CK, Galsky MD, Oh WK. PMID: 24433812.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    131. Is prostate cancer changing?: evolving patterns of metastatic castration-resistant prostate cancer. Cancer. 2014 Mar 15; 120(6):833-9. Doctor SM, Tsao CK, Godbold JH, Galsky MD, Oh WK. PMID: 25302607.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    132. Adverse event reporting in cancer clinical trial publications. J Clin Oncol. 2014 Jan 10; 32(2):83-9. Sivendran S, Latif A, McBride RB, Stensland KD, Wisnivesky J, Haines L, Oh WK, Galsky MD. PMID: 24323037.
      View in: PubMed   Mentions: 56     Fields:    Translation:Humans
    133. Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart review. Int J Oncol. 2014 Jan; 44(1):5-16. Oh WK, McDermott D, Porta C, Levy A, Elaidi R, Scotte F, Hawkins R, Castellano D, Bellmunt J, Rha SY, Sun JM, Nathan P, Feinberg BA, Scott J, McDermott R, Ahn JH, Wagstaff J, Chang YH, Ou YC, Donnellan P, Huang CY, McCaffrey J, Chiang PH, Chuang CK, Korves C, Neary MP, Diaz JR, Mehmud F, Duh MS. PMID: 24247547; PMCID: PMC3867384.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    134. TIMP-1 promotes accumulation of cancer associated fibroblasts and cancer progression. PLoS One. 2013; 8(10):e77366. Gong Y, Scott E, Lu R, Xu Y, Oh WK, Yu Q. PMID: 24143225; PMCID: PMC3797040.
      View in: PubMed   Mentions: 63     Fields:    Translation:HumansAnimalsCells
    135. Posttreatment prognostic nomogram for patients with metastatic urothelial cancer completing first-line cisplatin-based chemotherapy. Urol Oncol. 2014 Jan; 32(1):48.e1-8. Galsky MD, Moshier E, Krege S, Lin CC, Hahn N, Ecke T, Sonpavde G, Pond G, Godbold J, Oh WK, Bamias A. PMID: 24055428.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    136. Death or neurodevelopmental impairment at 18 to 22 months corrected age in a randomized trial of early dexamethasone to prevent death or chronic lung disease in extremely low birth weight infants. J Pediatr. 2014 Jan; 164(1):34-39.e2. Stark AR, Carlo WA, Vohr BR, Papile LA, Saha S, Bauer CR, Oh W, Shankaran S, Tyson JE, Wright LL, Poole WK, Das A, Stoll BJ, Fanaroff AA, Korones SB, Ehrenkranz RA, Stevenson DK, Peralta-Carcelen M, Wilson-Costello DE, Bada HS, Heyne RJ, Johnson YR, Lee KG, Steichen JJ, Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Ne. PMID: 23992673; PMCID: PMC4120744.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    137. Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: a systematic review and meta-analysis. Target Oncol. 2014 Sep; 9(3):195-204. Gartrell BA, Ying J, Sivendran S, Boucher KM, Choueiri TK, Sonpavde G, Oh WK, Agarwal N, Galsky MD. PMID: 23852656; PMCID: PMC4744485.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    138. Tumour angiogenesis: an elusive target in castration-resistant prostate cancer. Lancet Oncol. 2013 Jul; 14(8):681-2. Galsky MD, Oh WK. PMID: 23742876.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    139. Relationship between 6- and 9-month progression-free survival and overall survival in patients with metastatic urothelial cancer treated with first-line cisplatin-based chemotherapy. Cancer. 2013 Aug 15; 119(16):3020-6. Galsky MD, Krege S, Lin CC, Hahn N, Ecke T, Moshier E, Sonpavde G, Godbold J, Oh WK, Bamias A. PMID: 23720197.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    140. Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy. Cancer. 2013 Aug 15; 119(16):3012-9. Galsky MD, Moshier E, Krege S, Lin CC, Hahn N, Ecke T, Sonpavde G, Godbold J, Oh WK, Bamias A. PMID: 23720216.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    141. Metabolic complications with the use of mTOR inhibitors for cancer therapy. Cancer Treat Rev. 2014 Feb; 40(1):190-6. Sivendran S, Agarwal N, Gartrell B, Ying J, Boucher KM, Choueiri TK, Sonpavde G, Oh WK, Galsky MD. PMID: 23684373; PMCID: PMC4744486.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    142. The impact of gender on outcomes in patients with metastatic urothelial carcinoma. Clin Genitourin Cancer. 2013 Sep; 11(3):346-52. Haines L, Bamias A, Krege S, Lin CC, Hahn N, Ecke TH, Moshier E, Sonpavde G, Godbold J, Oh WK, Galsky MD. PMID: 23673281.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    143. Castration-resistant prostate cancer: AUA Guideline. J Urol. 2013 Aug; 190(2):429-38. Cookson MS, Roth BJ, Dahm P, Engstrom C, Freedland SJ, Hussain M, Lin DW, Lowrance WT, Murad MH, Oh WK, Penson DF, Kibel AS. PMID: 23665272.
      View in: PubMed   Mentions: 106     Fields:    Translation:Humans
    144. New paradigms in microtubule-mediated endocrine signaling in prostate cancer. Mol Cancer Ther. 2013 May; 12(5):555-66. Mistry SJ, Oh WK. PMID: 23635655.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    145. Metabolic and toxicological considerations of newly approved prostate cancer drugs. Expert Opin Drug Metab Toxicol. 2013 Jul; 9(7):835-46. Tsao CK, Liaw B, Yee T, Galsky MD, Oh WK. PMID: 23581700.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    146. Indomethacin prophylaxis to prevent intraventricular hemorrhage: association between incidence and timing of drug administration. J Pediatr. 2013 Sep; 163(3):706-10.e1. Mirza H, Oh W, Laptook A, Vohr B, Tucker R, Stonestreet BS. PMID: 23522865; PMCID: PMC3939677.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    147. Cisplatin-based combination chemotherapy in septuagenarians with metastatic urothelial cancer. Urol Oncol. 2014 Jan; 32(1):30.e15-21. Galsky MD, Krege S, Lin CC, Hahn N, Ecke TH, Moshier E, Sonpavde G, Godbold J, Oh WK, Bamias A. PMID: 23428534.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    148. Vitamin A supplementation in extremely low-birth-weight infants: subgroup analysis in small-for-gestational-age infants. Am J Perinatol. 2013 Oct; 30(9):771-80. Londhe VA, Nolen TL, Das A, Higgins RD, Tyson JE, Oh W, Devaskar SU, Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Ne. PMID: 23329565; PMCID: PMC3923571.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    149. Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the United States: a SEER analysis. World J Urol. 2013 Dec; 31(6):1535-9. Tsao CK, Small AC, Kates M, Moshier EL, Wisnivesky JP, Gartrell BA, Sonpavde G, Godbold JH, Palese MA, Hall SJ, Oh WK, Galsky MD. PMID: 23223962; PMCID: PMC4744480.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    150. Emerging personalized approaches for the management of advanced urothelial carcinoma. Expert Rev Anticancer Ther. 2012 Dec; 12(12):1537-43. Tsao CK, Gartrell BA, Oh WK, Galsky MD. PMID: 23253220; PMCID: PMC4744482.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    151. Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis. J Clin Oncol. 2012 Dec 10; 30(35):4416-26. Seng S, Liu Z, Chiu SK, Proverbs-Singh T, Sonpavde G, Choueiri TK, Tsao CK, Yu M, Hahn NM, Oh WK, Galsky MD. PMID: 23150697.
      View in: PubMed   Mentions: 90     Fields:    Translation:Humans
    152. Arterial thromboembolism in cancer patients treated with cisplatin: a systematic review and meta-analysis. J Natl Cancer Inst. 2012 Dec 05; 104(23):1837-40. Proverbs-Singh T, Chiu SK, Liu Z, Seng S, Sonpavde G, Choueiri TK, Tsao CK, Yu M, Hahn NM, Oh WK, Galsky MD. PMID: 23093559.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    153. A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study. Lancet Oncol. 2012 Nov; 13(11):1105-13. Ross RW, Galsky MD, Scher HI, Magidson J, Wassmann K, Lee GS, Katz L, Subudhi SK, Anand A, Fleisher M, Kantoff PW, Oh WK. PMID: 23059047.
      View in: PubMed   Mentions: 66     Fields:    Translation:Humans
    154. Urological cancer: Enzalutamide in metastatic CRPC-old dog, new tricks. Nat Rev Clin Oncol. 2012 Nov; 9(11):613-4. Tsao CK, Oh WK. PMID: 23044775.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimals
    155. Targeting the androgen receptor signalling axis in castration-resistant prostate cancer (CRPC). BJU Int. 2012 Dec; 110(11):1580-8. Tsao CK, Galsky MD, Small AC, Yee T, Oh WK. PMID: 22985411.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCells
    156. Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer. BJU Int. 2012 Dec; 110(11):1729-35. Nakabayashi M, Werner L, Courtney KD, Buckle G, Oh WK, Bubley GJ, Hayes JH, Weckstein D, Elfiky A, Sims DM, Kantoff PW, Taplin ME. PMID: 22928480.
      View in: PubMed   Mentions: 45     Fields:    Translation:HumansCTClinical Trials
    157. Atypical metastases from prostate cancer: 10-year experience at a single institution. AJR Am J Roentgenol. 2012 Aug; 199(2):367-72. Vinjamoori AH, Jagannathan JP, Shinagare AB, Taplin ME, Oh WK, Van den Abbeele AD, Ramaiya NH. PMID: 22826398.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    158. Bevacizumab treatment of prostate cancer. Expert Opin Biol Ther. 2012 Sep; 12(9):1241-9. Small AC, Oh WK. PMID: 22775507.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimals
    159. Prevalence and characteristics of patients with metastatic cancer who receive no anticancer therapy. Cancer. 2012 Dec 01; 118(23):5947-54. Small AC, Tsao CK, Moshier EL, Gartrell BA, Wisnivesky JP, Godbold JH, Smith CB, Sonpavde G, Oh WK, Galsky MD. PMID: 22707387.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    160. Spontaneous intestinal perforation in extremely low birth weight infants: association with indometacin therapy and effects on neurodevelopmental outcomes at 18-22 months corrected age. Arch Dis Child Fetal Neonatal Ed. 2013 Mar; 98(2):F127-32. Wadhawan R, Oh W, Vohr BR, Saha S, Das A, Bell EF, Laptook A, Shankaran S, Stoll BJ, Walsh MC, Higgins R. PMID: 22684157; PMCID: PMC3753803.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    161. Trends in the use of cytoreductive nephrectomy in the United States. Clin Genitourin Cancer. 2012 Sep; 10(3):159-63. Tsao CK, Small AC, Moshier EL, Gartrell BA, Wisnivesky JP, Sonpavde G, Godbold JH, Palese MA, Hall SJ, Oh WK, Galsky MD. PMID: 22651971; PMCID: PMC4744481.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    162. Treatment-related mortality with vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy in patients with advanced solid tumors: a meta-analysis. Cancer Treat Rev. 2012 Nov; 38(7):919-25. Sivendran S, Liu Z, Portas LJ, Yu M, Hahn N, Sonpavde G, Oh WK, Galsky MD. PMID: 22651902.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    163. Trends and variations in utilization of nephron-sparing procedures for stage I kidney cancer in the United States. World J Urol. 2013 Oct; 31(5):1211-7. Small AC, Tsao CK, Moshier EL, Gartrell BA, Wisnivesky JP, Godbold J, Sonpavde G, Palese MA, Hall SJ, Oh WK, Galsky MD. PMID: 22622394; PMCID: PMC4744479.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    164. The emerging role of circulating tumor cell detection in genitourinary cancer. J Urol. 2012 Jul; 188(1):21-6. Small AC, Gong Y, Oh WK, Hall SJ, van Rijn CJ, Galsky MD. PMID: 22578722.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCells
    165. Overcoming castration resistance in prostate cancer. Curr Opin Urol. 2012 May; 22(3):167-74. Tsao CK, Small AC, Galsky MD, Oh WK. PMID: 22472508.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimalsCells
    166. Clinical development of novel therapeutics for castration-resistant prostate cancer: historic challenges and recent successes. CA Cancer J Clin. 2012 Sep-Oct; 62(5):299-308. Galsky MD, Small AC, Tsao CK, Oh WK. PMID: 22535487.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    167. Hemodynamic effects of delayed cord clamping in premature infants. Pediatrics. 2012 Mar; 129(3):e667-72. Sommers R, Stonestreet BS, Oh W, Laptook A, Yanowitz TD, Raker C, Mercer J. PMID: 22331336; PMCID: PMC3356138.
      View in: PubMed   Mentions: 44     Fields:    Translation:Humans
    168. Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial. Cancer. 2012 Oct 01; 118(19):4777-84. Ross RW, Galsky MD, Febbo P, Barry M, Richie JP, Xie W, Fennessy FM, Bhatt RS, Hayes J, Choueiri TK, Tempany CM, Kantoff PW, Taplin ME, Oh WK. PMID: 22282219; PMCID: PMC3791849.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCTClinical Trials
    169. The effects of aggressive vs. conservative phototherapy on the brainstem auditory evoked responses of extremely-low-birth-weight infants. Pediatr Res. 2012 Jan; 71(1):77-84. Lasky RE, Church MW, Orlando MS, Morris BH, Parikh NA, Tyson JE, McDavid GE, Oh W, Stevenson DK, Van Meurs KP, Guillet R, Phelps DL. PMID: 22289854; PMCID: PMC3326602.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    170. Impact of the CKD-EPI equation for estimating renal function on eligibility for cisplatin-based chemotherapy in patients with urothelial cancer. Clin Genitourin Cancer. 2012 Mar; 10(1):15-20. Tsao CK, Moshier E, Seng SM, Godbold J, Grossman S, Winston J, Oh WK, Galsky MD. PMID: 22130294.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    171. Secondary hormonal therapy in men with castration-resistant prostate cancer. Clin Genitourin Cancer. 2011 Dec; 9(2):95-103. Nakabayashi M, Werner L, Oh WK, Regan MM, Kantoff PW, Taplin ME. PMID: 21958520.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    172. The impact of common genetic variations in genes of the sex hormone metabolic pathways on steroid hormone levels and prostate cancer aggressiveness. Cancer Prev Res (Phila). 2011 Dec; 4(12):2044-50. Sun T, Oh WK, Jacobus S, Regan M, Pomerantz M, Freedman ML, Lee GS, Kantoff PW. PMID: 21900597; PMCID: PMC3773969.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    173. Cytokines and neurodevelopmental outcomes in extremely low birth weight infants. J Pediatr. 2011 Dec; 159(6):919-25.e3. Carlo WA, McDonald SA, Tyson JE, Stoll BJ, Ehrenkranz RA, Shankaran S, Goldberg RN, Das A, Schendel D, Thorsen P, Skogstrand K, Hougaard DM, Oh W, Laptook AR, Duara S, Fanaroff AA, Donovan EF, Korones SB, Stevenson DK, Papile LA, Finer NN, O'Shea TM, Poindexter BB, Wright LL, Ambalavanan N, Higgins RD, Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Ne. PMID: 21798559; PMCID: PMC3215787.
      View in: PubMed   Mentions: 53     Fields:    Translation:Humans
    174. Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer. Urology. 2011 Sep; 78(3):626-30. Oh WK, Galsky MD, Stadler WM, Srinivas S, Chu F, Bubley G, Goddard J, Dunbar J, Ross RW. PMID: 21762967; PMCID: PMC3166448.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansCTClinical Trials
    175. Retrospective analysis of satraplatin in patients with metastatic urothelial cancer refractory to standard platinum-based chemotherapy. Clin Genitourin Cancer. 2011 Sep; 9(1):27-30. Galsky MD, Seng S, Camacho LH, Chiorean EG, Mulkerin D, Hong DS, Oh WK, Bajorin DF. PMID: 21700509.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    176. Early nutrition mediates the influence of severity of illness on extremely LBW infants. Pediatr Res. 2011 Jun; 69(6):522-9. Ehrenkranz RA, Das A, Wrage LA, Poindexter BB, Higgins RD, Stoll BJ, Oh W, Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Ne. PMID: 21378596; PMCID: PMC3090495.
      View in: PubMed   Mentions: 76     Fields:    Translation:Humans
    177. Clinical development of cabazitaxel for the treatment of castration-resistant prostate cancer. Clin Med Insights Oncol. 2011; 5:163-9. Tsao CK, Seng S, Oh WK, Galsky MD. PMID: 21695098; PMCID: PMC3117627.
      View in: PubMed   Mentions: 6  
    178. SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer. J Clin Oncol. 2011 Jun 20; 29(18):2565-73. Yang M, Xie W, Mostaghel E, Nakabayashi M, Werner L, Sun T, Pomerantz M, Freedman M, Ross R, Regan M, Sharifi N, Figg WD, Balk S, Brown M, Taplin ME, Oh WK, Lee GS, Kantoff PW. PMID: 21606417; PMCID: PMC3138634.
      View in: PubMed   Mentions: 88     Fields:    Translation:Humans
    179. Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy. J Clin Oncol. 2011 Jun 10; 29(17):2432-8. Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK, Dreicer R, Vogelzang N, Sternberg CN, Bajorin DF, Bellmunt J. PMID: 21555688.
      View in: PubMed   Mentions: 203     Fields:    Translation:Humans
    180. PC3 is a cell line characteristic of prostatic small cell carcinoma. Prostate. 2011 Nov; 71(15):1668-79. Tai S, Sun Y, Squires JM, Zhang H, Oh WK, Liang CZ, Huang J. PMID: 21432867; PMCID: PMC3426349.
      View in: PubMed   Mentions: 229     Fields:    Translation:HumansAnimalsCells
    181. Germline CAG repeat length of the androgen receptor and time to progression in patients with prostate cancer treated with androgen deprivation therapy. BJU Int. 2011 Oct; 108(7):1086-91. Misra D, Xie W, Regan MM, Ross RW, Lee GS, Germain D, Kantoff PW, Oh WK. PMID: 21410629.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    182. Association of prostate cancer risk Loci with disease aggressiveness and prostate cancer-specific mortality. Cancer Prev Res (Phila). 2011 May; 4(5):719-28. Pomerantz MM, Werner L, Xie W, Regan MM, Lee GS, Sun T, Evan C, Petrozziello G, Nakabayashi M, Oh WK, Kantoff PW, Freedman ML. PMID: 21367958; PMCID: PMC3811002.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    183. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol. 2011 Mar; 12(3):211-4. Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK, Dreicer R, Vogelzang N, Sternberg C, Bajorin DF, Bellmunt J. PMID: 21376284.
      View in: PubMed   Mentions: 97     Fields:    Translation:Humans
    184. Neurodevelopmental outcomes of triplets or higher-order extremely low birth weight infants. Pediatrics. 2011 Mar; 127(3):e654-60. Wadhawan R, Oh W, Vohr BR, Wrage L, Das A, Bell EF, Laptook AR, Shankaran S, Stoll BJ, Walsh MC, Higgins RD, Eunice Kennedy Shriver National Institute of Child Health & Human Development Neonatal Research Netw. PMID: 21357334; PMCID: PMC3304548.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    185. Is phototherapy exposure associated with better or worse outcomes in 501- to 1000-g-birth-weight infants? Acta Paediatr. 2011 Jul; 100(7):960-5. Hintz SR, Stevenson DK, Yao Q, Wong RJ, Das A, Van Meurs KP, Morris BH, Tyson JE, Oh W, Poole WK, Phelps DL, McDavid GE, Grisby C, Higgins RD, Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Ne. PMID: 21272067; PMCID: PMC3505994.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    186. Congenital hypothyroidism with a delayed thyroid-stimulating hormone elevation in very premature infants: incidence and growth and developmental outcomes. J Pediatr. 2011 Apr; 158(4):538-42. Woo HC, Lizarda A, Tucker R, Mitchell ML, Vohr B, Oh W, Phornphutkul C. PMID: 21232766.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansPHPublic Health
    187. Single-nucleotide polymorphisms within the antioxidant defence system and associations with aggressive prostate cancer. BJU Int. 2011 Jan; 107(1):126-34. Abe M, Xie W, Regan MM, King IB, Stampfer MJ, Kantoff PW, Oh WK, Chan JM. PMID: 20477822; PMCID: PMC3010266.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    188. Inherited variants in the chemokine CCL2 gene and prostate cancer aggressiveness in a Caucasian cohort. Clin Cancer Res. 2011 Mar 15; 17(6):1546-52. Sun T, Mary LG, Oh WK, Freedman ML, Pomerantz M, Pienta KJ, Kantoff PW. PMID: 21135144; PMCID: PMC3060307.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    189. Predictors of survival in patients with prostate cancer and spinal metastasis. Presented at the 2009 Joint Spine Section Meeting. Clinical article. J Neurosurg Spine. 2010 Dec; 13(6):789-94. Drzymalski DM, Oh WK, Werner L, Regan MM, Kantoff P, Tuli S. PMID: 21121759.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    190. Selective cell death mediated by small conditional RNAs: a novel therapeutic approach to cancer therapy. Asian J Androl. 2011 Mar; 13(2):181-2. Tsao CK, Oh WK. PMID: 21076441; PMCID: PMC3739191.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    191. Analysis of the 10q11 cancer risk locus implicates MSMB and NCOA4 in human prostate tumorigenesis. PLoS Genet. 2010 Nov 11; 6(11):e1001204. Pomerantz MM, Shrestha Y, Flavin RJ, Regan MM, Penney KL, Mucci LA, Stampfer MJ, Hunter DJ, Chanock SJ, Schafer EJ, Chan JA, Tabernero J, Baselga J, Richardson AL, Loda M, Oh WK, Kantoff PW, Hahn WC, Freedman ML. PMID: 21085629; PMCID: PMC2978684.
      View in: PubMed   Mentions: 54     Fields:    Translation:HumansCells
    192. Recurrence-free survival in prostate cancer is related to increased stromal TRAIL expression. Cancer. 2011 Mar 15; 117(6):1172-82. Anees M, Horak P, El-Gazzar A, Susani M, Heinze G, Perco P, Loda M, Lis R, Krainer M, Oh WK. PMID: 21381010.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    193. Cancer therapy from bench to bedside. Mt Sinai J Med. 2010 Nov-Dec; 77(6):571-2. Oh WK, Burakoff SJ. PMID: 21105120.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    194. Genome-wide association study of prostate cancer mortality. Cancer Epidemiol Biomarkers Prev. 2010 Nov; 19(11):2869-76. Penney KL, Pyne S, Schumacher FR, Sinnott JA, Mucci LA, Kraft PL, Ma J, Oh WK, Kurth T, Kantoff PW, Giovannucci EL, Stampfer MJ, Hunter DJ, Freedman ML. PMID: 20978177; PMCID: PMC3197738.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    195. Costs associated with angiogenesis inhibitor therapies for metastatic renal cell carcinoma in clinical practice: results from a medical chart review study. Urol Oncol. 2012 Nov-Dec; 30(6):848-55. Choueiri TK, McDermott D, Sheng Duh M, Sarda SP, Neary MP, Oh WK. PMID: 20926319.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    196. Elevated plasma tissue inhibitor of metalloproteinase-1 levels predict decreased survival in castration-resistant prostate cancer patients. Cancer. 2011 Feb 01; 117(3):517-25. Oh WK, Vargas R, Jacobus S, Leitzel K, Regan MM, Hamer P, Pierce K, Brown-Shimer S, Carney W, Ali SM, Kantoff PW, Lipton A. PMID: 20862742.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    197. Single-nucleotide polymorphisms in p53 pathway and aggressiveness of prostate cancer in a Caucasian population. Clin Cancer Res. 2010 Nov 01; 16(21):5244-51. Sun T, Lee GS, Oh WK, Pomerantz M, Yang M, Xie W, Freedman ML, Kantoff PW. PMID: 20855462; PMCID: PMC2970725.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCells
    198. Cabazitaxel. Nat Rev Drug Discov. 2010 Sep; 9(9):677-8. Galsky MD, Dritselis A, Kirkpatrick P, Oh WK. PMID: 20811375.
      View in: PubMed   Mentions: 54     Fields:    Translation:Humans
    199. Inherited variations in AR, ESR1, and ESR2 genes are not associated with prostate cancer aggressiveness or with efficacy of androgen deprivation therapy. Cancer Epidemiol Biomarkers Prev. 2010 Jul; 19(7):1871-8. Sun T, Lee GS, Werner L, Pomerantz M, Oh WK, Kantoff PW, Freedman ML. PMID: 20615892; PMCID: PMC3755451.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    200. A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC). Invest New Drugs. 2011 Dec; 29(6):1465-74. Harrison MR, Hahn NM, Pili R, Oh WK, Hammers H, Sweeney C, Kim K, Perlman S, Arnott J, Sidor C, Wilding G, Liu G. PMID: 20499131; PMCID: PMC3042040.
      View in: PubMed   Mentions: 48     Fields:    Translation:HumansCTClinical Trials
    201. Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma. Urol Oncol. 2011 Nov-Dec; 29(6):756-63. Elfiky AA, Cho DC, McDermott DF, Rosenberg JE, Fortner B, Antràs L, Chen K, Sheng Duh M, Jayawant SS, Oh WK, Atkins MB, Choueiri TK. PMID: 20451414.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    202. Castration-resistant prostate cancer: new science and therapeutic prospects. Ther Adv Med Oncol. 2010 May; 2(3):189-207. Bellmunt J, Oh WK. PMID: 21789134; PMCID: PMC3126017.
      View in: PubMed   Mentions: 9  
    203. Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy. BJU Int. 2010 Sep; 106(6):772-8. Choueiri TK, Regan MM, Rosenberg JE, Oh WK, Clement J, Amato AM, McDermott D, Cho DC, Atkins MB, Signoretti S. PMID: 20230385.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    204. Dilemmas and controversies in the management of prostate cancer continue to present a vexing challenge to physicians and patients dealing with the disease. Preface. Urol Clin North Am. 2010 Feb; 37(1):xiii. Oh WK, Hu JC. PMID: 20152513.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    205. Does oral antiandrogen use before leuteinizing hormone-releasing hormone therapy in patients with metastatic prostate cancer prevent clinical consequences of a testosterone flare? Urology. 2010 Mar; 75(3):642-7. Oh WK, Landrum MB, Lamont EB, McNeil BJ, Keating NL. PMID: 19962733.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    206. Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer. Clin Cancer Res. 2009 Nov 15; 15(22):7099-105. Taplin ME, Regan MM, Ko YJ, Bubley GJ, Duggan SE, Werner L, Beer TM, Ryan CW, Mathew P, Tu SM, Denmeade SR, Oh WK, Sartor O, Mantzoros CS, Rittmaster R, Kantoff PW, Balk SP. PMID: 19887483; PMCID: PMC3644858.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansCTClinical Trials
    207. Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review. BJU Int. 2010 May; 105(9):1247-54. Choueiri TK, Duh MS, Clement J, Brick AJ, Rogers MJ, Kwabi C, Shah K, Percy AG, Antràs L, Jayawant SS, Chen K, Wang ST, Luka A, Neary MP, McDermott D, Oh WK. PMID: 19863525.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    208. Activity of ketoconazole after taxane-based chemotherapy in castration-resistant prostate cancer. BJU Int. 2010 May; 105(10):1392-6. Nakabayashi M, Oh WK, Jacobus S, Regan MM, Taplin ME, Kantoff PW, Rosenberg JE. PMID: 19863532.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    209. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009 Dec 01; 27(34):5794-9. Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C, McDermott DF, Oh WK, Atkins MB, Bukowski RM, Rini BI, Choueiri TK. PMID: 19826129.
      View in: PubMed   Mentions: 783     Fields:    Translation:Humans
    210. The mechanism of action of estrogen in castration-resistant prostate cancer: clues from hormone levels. Clin Genitourin Cancer. 2009 Oct; 7(3):E71-6. Aggarwal R, Weinberg V, Small EJ, Oh W, Rushakoff R, Ryan CJ. PMID: 19815485.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    211. Activity of dutasteride plus ketoconazole in castration-refractory prostate cancer after progression on ketoconazole alone. Clin Genitourin Cancer. 2009 Oct; 7(3):E90-2. Sartor O, Nakabayashi M, Taplin ME, Ross RW, Kantoff PW, Balk SP, Oh WK. PMID: 19815488.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    212. Metastatic seminoma and grade 1 follicular lymphoma presenting concurrently in a supraclavicular lymph node: a case report. Cases J. 2009 Aug 19; 2:7273. Jacobsen E, Chen JH, Schurko B, Benson C, Oh WK. PMID: 19918516; PMCID: PMC2769346.
      View in: PubMed   Mentions: 1  
    213. Functional enhancers at the gene-poor 8q24 cancer-linked locus. PLoS Genet. 2009 Aug; 5(8):e1000597. Jia L, Landan G, Pomerantz M, Jaschek R, Herman P, Reich D, Yan C, Khalid O, Kantoff P, Oh W, Manak JR, Berman BP, Henderson BE, Frenkel B, Haiman CA, Freedman M, Tanay A, Coetzee GA. PMID: 19680443; PMCID: PMC2717370.
      View in: PubMed   Mentions: 148     Fields:    Translation:HumansCells
    214. Cost implications of IV versus oral anti-angiogenesis therapies in patients with advanced renal cell carcinoma: retrospective claims database analysis. Curr Med Res Opin. 2009 Aug; 25(8):2081-90. Duh MS, Dial E, Choueiri TK, Fournier AA, Antras L, Rodermund D, Neary MP, Oh WK. PMID: 19586325.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    215. Evaluation of the 8q24 prostate cancer risk locus and MYC expression. Cancer Res. 2009 Jul 01; 69(13):5568-74. Pomerantz MM, Beckwith CA, Regan MM, Wyman SK, Petrovics G, Chen Y, Hawksworth DJ, Schumacher FR, Mucci L, Penney KL, Stampfer MJ, Chan JA, Ardlie KG, Fritz BR, Parkin RK, Lin DW, Dyke M, Herman P, Lee S, Oh WK, Kantoff PW, Tewari M, McLeod DG, Srivastava S, Freedman ML. PMID: 19549893; PMCID: PMC2884104.
      View in: PubMed   Mentions: 69     Fields:    Translation:HumansCells
    216. Plasma selenium, manganese superoxide dismutase, and intermediate- or high-risk prostate cancer. J Clin Oncol. 2009 Aug 01; 27(22):3577-83. Chan JM, Oh WK, Xie W, Regan MM, Stampfer MJ, King IB, Abe M, Kantoff PW. PMID: 19528373; PMCID: PMC2720077.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    217. Evaluation of 8q24 and 17q risk loci and prostate cancer mortality. Clin Cancer Res. 2009 May 01; 15(9):3223-30. Penney KL, Salinas CA, Pomerantz M, Schumacher FR, Beckwith CA, Lee GS, Oh WK, Sartor O, Ostrander EA, Kurth T, Ma J, Mucci L, Stanford JL, Kantoff PW, Hunter DJ, Stampfer MJ, Freedman ML. PMID: 19366828; PMCID: PMC2878092.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCells
    218. Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy. Cancer. 2009 Mar 01; 115(5):981-7. Choueiri TK, Xie W, D'Amico AV, Ross RW, Hu JC, Pomerantz M, Regan MM, Taplin ME, Kantoff PW, Sartor O, Oh WK. PMID: 19152438; PMCID: PMC2931827.
      View in: PubMed   Mentions: 49     Fields:    Translation:Humans
    219. Novel therapeutic strategies in prostate cancer: establishing a stratification system for patient selection in targeted trials. IDrugs. 2009 Mar; 12(3):165-8. Priolo C, Oh WK, Loda M. PMID: 19333896.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimals
    220. Twin gestation and neurodevelopmental outcome in extremely low birth weight infants. Pediatrics. 2009 Feb; 123(2):e220-7. Wadhawan R, Oh W, Perritt RL, McDonald SA, Das A, Poole WK, Vohr BR, Higgins RD. PMID: 19139085; PMCID: PMC2842087.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    221. Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research. Clin Genitourin Cancer. 2009 Jan; 7(1):51-7. Morris MJ, Basch EM, Wilding G, Hussain M, Carducci MA, Higano C, Kantoff P, Oh WK, Small EJ, George D, Mathew P, Beer TM, Slovin SF, Ryan C, Logothetis C, Scher HI. PMID: 19213669; PMCID: PMC3394090.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    222. Absence of relationship between steroid hormone levels and prostate cancer tumor grade. Urology. 2009 Feb; 73(2):356-61; discussion 361-2. Sher DJ, Mantzoros C, Jacobus S, Regan MM, Lee GS, Oh WK. PMID: 19036418.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    223. What is the current status of second-line chemotherapy for castration-resistant prostate cancer? Nat Clin Pract Urol. 2008 Dec; 5(12):650-1. Rosenberg JE, Oh WK. PMID: 18936787.
      View in: PubMed   Mentions:    Fields:    
    224. CD44 expression is a feature of prostatic small cell carcinoma and distinguishes it from its mimickers. Hum Pathol. 2009 Feb; 40(2):252-8. Simon RA, di Sant'Agnese PA, Huang LS, Xu H, Yao JL, Yang Q, Liang S, Liu J, Yu R, Cheng L, Oh WK, Palapattu GS, Wei J, Huang J. PMID: 18835619.
      View in: PubMed   Mentions: 35     Fields:    Translation:Humans
    225. Relationship between serum adiponectin and prostate cancer grade. Prostate. 2008 Oct 01; 68(14):1592-8. Sher DJ, Oh WK, Jacobus S, Regan MM, Lee GS, Mantzoros C. PMID: 18646046.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    226. Docetaxel chemotherapy remains the standard of care in castration-resistant prostate cancer. Nat Clin Pract Oncol. 2008 Sep; 5(9):506-7. Schurko B, Oh WK. PMID: 18648352.
      View in: PubMed   Mentions: 13     Fields:    
    227. Association between urinary lactate to creatinine ratio and neurodevelopmental outcome in term infants with hypoxic-ischemic encephalopathy. J Pediatr. 2008 Sep; 153(3):375-8. Oh W, Perritt R, Shankaran S, Merritts M, Donovan EF, Ehrenkranz RA, O'Shea TM, Tyson JE, Laptook AR, Das A, Higgins RD. PMID: 18534246; PMCID: PMC2953792.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    228. A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones. BJU Int. 2008 May; 101(9):1084-9. Taplin ME, Manola J, Oh WK, Kantoff PW, Bubley GJ, Smith M, Barb D, Mantzoros C, Gelmann EP, Balk SP. PMID: 18399827.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansCTClinical Trials
    229. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect. Cancer. 2008 Mar 15; 112(6):1247-53. Ross RW, Xie W, Regan MM, Pomerantz M, Nakabayashi M, Daskivich TJ, Sartor O, Taplin ME, Kantoff PW, Oh WK. PMID: 18293426.
      View in: PubMed   Mentions: 62     Fields:    Translation:Humans
    230. Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer. J Clin Oncol. 2008 Feb 20; 26(6):842-7. Ross RW, Oh WK, Xie W, Pomerantz M, Nakabayashi M, Sartor O, Taplin ME, Regan MM, Kantoff PW, Freedman M. PMID: 18281655.
      View in: PubMed   Mentions: 50     Fields:    Translation:Humans
    231. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel. Cancer. 2008 Feb 01; 112(3):521-6. Ross RW, Beer TM, Jacobus S, Bubley GJ, Taplin ME, Ryan CW, Huang J, Oh WK, Prostate Cancer Clinical Trials Consortium. PMID: 18085595.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansCTClinical Trials
    232. Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer. BJU Int. 2008 Feb; 101(3):308-12. Nakabayashi M, Sartor O, Jacobus S, Regan MM, McKearn D, Ross RW, Kantoff PW, Taplin ME, Oh WK. PMID: 18184327.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    233. Use of androgen deprivation therapy for metastatic prostate cancer in older men. BJU Int. 2008 May; 101(9):1077-83. Keating NL, O'Malley AJ, McNaughton-Collins M, Oh WK, Smith MR. PMID: 18190632; PMCID: PMC2900629.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    234. Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphatase. Cancer. 2007 Dec 15; 110(12):2709-15. Xie W, Nakabayashi M, Regan MM, Oh WK. PMID: 17960608.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    235. Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clin Cancer Res. 2007 Oct 01; 13(19):5816-24. Mathew P, Thall PF, Bucana CD, Oh WK, Morris MJ, Jones DM, Johnson MM, Wen S, Pagliaro LC, Tannir NM, Tu SM, Meluch AA, Smith L, Cohen L, Kim SJ, Troncoso P, Fidler IJ, Logothetis CJ. PMID: 17908974.
      View in: PubMed   Mentions: 47     Fields:    Translation:Humans
    236. Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. J Immunother. 2007 Oct; 30(7):749-61. Avigan DE, Vasir B, George DJ, Oh WK, Atkins MB, McDermott DF, Kantoff PW, Figlin RA, Vasconcelles MJ, Xu Y, Kufe D, Bukowski RM. PMID: 17893567.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
    237. Distinct prognostic role of prostate-specific antigen doubling time and velocity at emergence of androgen independence in patients treated with chemotherapy. Urology. 2007 Sep; 70(3):527-31. Daskivich TJ, Regan MM, Oh WK. PMID: 17905110.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    238. Human milk intake and retinopathy of prematurity in extremely low birth weight infants. Pediatrics. 2007 Jul; 120(1):1-9. Heller CD, O'Shea M, Yao Q, Langer J, Ehrenkranz RA, Phelps DL, Poole WK, Stoll B, Duara S, Oh W, Lemons J, Poindexter B, NICHD Neonatal Research Network. PMID: 17606555.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    239. Phase II study of low dose and high dose conjugated estrogen for androgen independent prostate cancer. J Urol. 2007 Jun; 177(6):2146-50. Pomerantz M, Manola J, Taplin ME, Bubley G, Inman M, Lowell J, Beard C, Kantoff PW, Oh WK. PMID: 17509304.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    240. Timing of umbilical cord clamping at birth in full-term infants. JAMA. 2007 Mar 21; 297(11):1257-8. Oh W. PMID: 17374821.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    241. The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid. Cancer. 2007 Mar 15; 109(6):1090-6. Oh WK, Proctor K, Nakabayashi M, Evan C, Tormey LK, Daskivich T, Antràs L, Smith M, Neary MP, Duh MS. PMID: 17311345.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    242. Response to vinorelbine with or without estramustine as second-line chemotherapy in patients with hormone-refractory prostate cancer. Cancer J. 2007 Mar-Apr; 13(2):125-9. Nakabayashi M, Ling J, Xie W, Regan MM, Oh WK. PMID: 17476141.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    243. Is there a role for platinum chemotherapy in the treatment of patients with hormone-refractory prostate cancer? Cancer. 2007 Feb 01; 109(3):477-86. Oh WK, Tay MH, Huang J. PMID: 17186531.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    244. Trends in neonatal morbidity and mortality for very low birthweight infants. Am J Obstet Gynecol. 2007 Feb; 196(2):147.e1-8. Fanaroff AA, Stoll BJ, Wright LL, Carlo WA, Ehrenkranz RA, Stark AR, Bauer CR, Donovan EF, Korones SB, Laptook AR, Lemons JA, Oh W, Papile LA, Shankaran S, Stevenson DK, Tyson JE, Poole WK, NICHD Neonatal Research Network. PMID: 17306659.
      View in: PubMed   Mentions: 392     Fields:    Translation:Humans
    245. Indomethacin prophylaxis for preterm infants: the impact of 2 multicentered randomized controlled trials on clinical practice. J Pediatr. 2007 Jan; 150(1):46-50.e2. Clyman RI, Saha S, Jobe A, Oh W. PMID: 17188612; PMCID: PMC1849955.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    246. Prostate specific antigen doubling time calculation: not as easy as 1, 2, 4. J Urol. 2006 Nov; 176(5):1927-37. Daskivich TJ, Regan MM, Oh WK. PMID: 17070213.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    247. Treatment of a radiation-induced rectal ulcer with hyperbaric oxygen therapy in a man with prostate cancer. Urol Oncol. 2006 Nov-Dec; 24(6):503-8. Nakabayashi M, Beard C, Kelly SM, Carr-Locke DL, Oh WK. PMID: 17138131.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansPHPublic Health
    248. The medical management of prostate cancer: a multidisciplinary team approach. BJU Int. 2007 Jan; 99(1):22-7. Sternberg CN, Krainer M, Oh WK, Bracarda S, Bellmunt J, Ozen H, Zlotta A, Beer TM, Oudard S, Rauchenwald M, Skoneczna I, Borner MM, Fitzpatrick JM. PMID: 16956362.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    249. Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer. Cancer. 2006 Sep 01; 107(5):975-81. Nakabayashi M, Xie W, Regan MM, Jackman DM, Kantoff PW, Oh WK. PMID: 16862573.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    250. Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer. Cancer. 2006 Aug 01; 107(3):530-5. Michaelson MD, Kaufman DS, Kantoff P, Oh WK, Smith MR. PMID: 16804927.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    251. Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy. J Clin Oncol. 2006 Jun 20; 24(18):2723-8. Smith MR, Manola J, Kaufman DS, Oh WK, Bubley GJ, Kantoff PW. PMID: 16782912.
      View in: PubMed   Mentions: 49     Fields:    Translation:Humans
    252. Treatment of bicalutamide-induced gynecomastia with breast-reduction surgery in prostate cancer. J Clin Oncol. 2006 Jun 20; 24(18):2958-9. Nakabayashi M, Bartlett RA, Oh WK. PMID: 16782932.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    253. Carboplatin for stage I seminoma. J Clin Oncol. 2006 Jun 20; 24(18):2971-2; author reply e32-3. Gilligan T, Oh WK, Kantoff PW. PMID: 16782940.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    254. Development of an integrated prostate cancer research information system. Clin Genitourin Cancer. 2006 Jun; 5(1):61-6. Oh WK, Hayes J, Evan C, Manola J, George DJ, Waldron H, Donovan M, Varner J, Orechia J, Katcher B, Lu D, Nevins A, Wright RL, Tormey L, Talcott J, Rubin MA, Loda M, Sellers WR, Richie JP, Kantoff PW, Weeks J. PMID: 16859581.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    255. Oral probiotics prevent necrotizing enterocolitis. J Pediatr. 2006 Jun; 148(6):849; author reply 850. Lin HC, Su BH, Oh W. PMID: 16769410.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    256. Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes. Urology. 2006 Jun; 67(6):1235-40. Oh WK, Manola J, Babcic V, Harnam N, Kantoff PW. PMID: 16765185.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    257. Recent progress in hormonal therapy for advanced prostate cancer. Curr Opin Urol. 2006 May; 16(3):173-8. Daskivich TJ, Oh WK. PMID: 16679855.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    258. Failure of gonadotropin-releasing hormone agonists with and without sterile abscess formation at depot sites: insight into mechanisms? Urology. 2006 May; 67(5):1084.e15-7. Daskivich TJ, Oh WK. PMID: 16698377.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    259. Chemotherapy for high-risk localized prostate cancer. BJU Int. 2006 Apr; 97(4):679-83. Nakabayashi M, Oh WK. PMID: 16536752.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    260. Delayed cord clamping in very preterm infants reduces the incidence of intraventricular hemorrhage and late-onset sepsis: a randomized, controlled trial. Pediatrics. 2006 Apr; 117(4):1235-42. Mercer JS, Vohr BR, McGrath MM, Padbury JF, Wallach M, Oh W. PMID: 16585320; PMCID: PMC1564438.
      View in: PubMed   Mentions: 75     Fields:    Translation:Humans
    261. A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma: second line taxane-based therapy after first-line epothilone-B analog ixabepilone (BMS-247550) therapy. Cancer. 2006 Jan 01; 106(1):58-62. Rosenberg JE, Galsky MD, Rohs NC, Weinberg VK, Oh WK, Kelly WK, Small EJ. PMID: 16329138.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    262. Application of oligonucleotide microarrays to assess the biological effects of neoadjuvant imatinib mesylate treatment for localized prostate cancer. Clin Cancer Res. 2006 Jan 01; 12(1):152-8. Febbo PG, Thorner A, Rubin MA, Loda M, Kantoff PW, Oh WK, Golub T, George D. PMID: 16397037.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    263. Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months. Pediatrics. 2006 Jan; 117(1):84-92. Benjamin DK, Stoll BJ, Fanaroff AA, McDonald SA, Oh W, Higgins RD, Duara S, Poole K, Laptook A, Goldberg R, National Institute of Child Health and Human Development Neonatal Research Network. PMID: 16396864.
      View in: PubMed   Mentions: 194     Fields:    Translation:Humans
    264. Association between fluid intake and weight loss during the first ten days of life and risk of bronchopulmonary dysplasia in extremely low birth weight infants. J Pediatr. 2005 Dec; 147(6):786-90. Oh W, Poindexter BB, Perritt R, Lemons JA, Bauer CR, Ehrenkranz RA, Stoll BJ, Poole K, Wright LL, Neonatal Research Network. PMID: 16356432.
      View in: PubMed   Mentions: 82     Fields:    Translation:Humans
    265. Whole-body hypothermia for neonates with hypoxic-ischemic encephalopathy. N Engl J Med. 2005 Oct 13; 353(15):1574-84. Shankaran S, Laptook AR, Ehrenkranz RA, Tyson JE, McDonald SA, Donovan EF, Fanaroff AA, Poole WK, Wright LL, Higgins RD, Finer NN, Carlo WA, Duara S, Oh W, Cotten CM, Stevenson DK, Stoll BJ, Lemons JA, Guillet R, Jobe AH, National Institute of Child Health and Human Development Neonatal Research Network. PMID: 16221780.
      View in: PubMed   Mentions: 864     Fields:    Translation:HumansCTClinical Trials
    266. High-risk localized prostate cancer: integrating chemotherapy. Oncologist. 2005 Oct; 10 Suppl 2:18-22. Oh WK. PMID: 16272455.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    267. Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer. BJU Int. 2005 Oct; 96(6):783-6. Nakabayashi M, Regan MM, Lifsey D, Kantoff PW, Taplin ME, Sartor O, Oh WK. PMID: 16153200.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    268. Prolonged hospital stay for extremely premature infants: risk factors, center differences, and the impact of mortality on selecting a best-performing center. J Perinatol. 2005 Oct; 25(10):650-5. Cotten CM, Oh W, McDonald S, Carlo W, Fanaroff AA, Duara S, Stoll B, Laptook A, Poole K, Wright LL, Goldberg RN, NICHD Neonatal Research Network. PMID: 16079906.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    269. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res. 2005 Jul 15; 11(14):5233-40. Febbo PG, Richie JP, George DJ, Loda M, Manola J, Shankar S, Barnes AS, Tempany C, Catalona W, Kantoff PW, Oh WK. PMID: 16033841.
      View in: PubMed   Mentions: 55     Fields:    Translation:HumansCTClinical Trials
    270. Inhaled nitric oxide for premature infants with severe respiratory failure. N Engl J Med. 2005 Jul 07; 353(1):13-22. Van Meurs KP, Wright LL, Ehrenkranz RA, Lemons JA, Ball MB, Poole WK, Perritt R, Higgins RD, Oh W, Hudak ML, Laptook AR, Shankaran S, Finer NN, Carlo WA, Kennedy KA, Fridriksson JH, Steinhorn RH, Sokol GM, Konduri GG, Aschner JL, Stoll BJ, D'Angio CT, Stevenson DK, Preemie Inhaled Nitric Oxide Study. PMID: 16000352.
      View in: PubMed   Mentions: 78     Fields:    Translation:HumansCTClinical Trials
    271. Very low birth weight preterm infants with early onset neonatal sepsis: the predominance of gram-negative infections continues in the National Institute of Child Health and Human Development Neonatal Research Network, 2002-2003. Pediatr Infect Dis J. 2005 Jul; 24(7):635-9. Stoll BJ, Hansen NI, Higgins RD, Fanaroff AA, Duara S, Goldberg R, Laptook A, Walsh M, Oh W, Hale E, National Institute of Child Health and Human Development. PMID: 15999007.
      View in: PubMed   Mentions: 107     Fields:    Translation:Humans
    272. Response to docetaxel/carboplatin in patients with hormone-refractory prostate cancer not responding to taxane-based chemotherapy. Clin Prostate Cancer. 2005 Jun; 4(1):61-4. Oh WK, George DJ, Tay MH. PMID: 15992464.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    273. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol. 2005 Mar 01; 23(7):1439-46. Galsky MD, Small EJ, Oh WK, Chen I, Smith DC, Colevas AD, Martone L, Curley T, Delacruz A, Scher HI, Kelly WK. PMID: 15735119.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansCTClinical Trials
    274. Oral probiotics reduce the incidence and severity of necrotizing enterocolitis in very low birth weight infants. Pediatrics. 2005 Jan; 115(1):1-4. Lin HC, Su BH, Chen AC, Lin TW, Tsai CH, Yeh TF, Oh W. PMID: 15629973.
      View in: PubMed   Mentions: 163     Fields:    Translation:HumansCellsCTClinical Trials
    275. A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer. Clin Cancer Res. 2005 Jan 01; 11(1):284-9. Oh WK, Hagmann E, Manola J, George DJ, Gilligan TD, Jacobson JO, Smith MR, Kaufman DS, Kantoff PW. PMID: 15671557.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    276. Prevention of intraventricular hemorrhage by indomethacin in male preterm infants. J Pediatr. 2004 Dec; 145(6):832-4. Ment LR, Vohr BR, Makuch RW, Westerveld M, Katz KH, Schneider KC, Duncan CC, Ehrenkranz R, Oh W, Philip AG, Scott DT, Allan WC. PMID: 15580211.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansCTClinical Trials
    277. An overview of chemotherapy trials in localized and recurrent nonmetastatic prostate cancer. J Urol. 2004 Nov; 172(5 Pt 2):S34-7; discussion S37. Oh WK. PMID: 15535440.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    278. Fourth International Conference on Innovations and Challenges in Prostate Cancer: Prevention, Detection and Treatment. J Urol. 2004 Nov; 172(5 Pt 2):S3-5. Carroll PR, Chan JM, D'Amico AV, Gelmann EP, Iversen P, Klotz L, Nelson JB, Nelson PS, Nelson WG, Oh WK, Rosen N, Rubin MA, Sandler H, Sellers WR, Smith MR, Xu J, McMann MC, Kantoff PW. PMID: 15535434.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    279. Neoadjuvant and adjuvant chemotherapy for high-risk localized prostate cancer. Curr Treat Options Oncol. 2004 Oct; 5(5):349-55. Nakabayashi M, Oh WK. PMID: 15341673.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    280. Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy. Cancer. 2004 Oct 01; 101(7):1569-74. Smith MR, Manola J, Kaufman DS, George D, Oh WK, Mueller E, Slovin S, Spiegelman B, Small E, Kantoff PW. PMID: 15468186.
      View in: PubMed   Mentions: 54     Fields:    Translation:HumansCTClinical Trials
    281. A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer. Urol Oncol. 2004 Sep-Oct; 22(5):393-7. Kaufman DS, Carducci MA, Kuzel TM, Todd MB, Oh WK, Smith MR, Ye Z, Nicol SJ, Stadler WM. PMID: 15464919.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    282. Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer. J Clin Oncol. 2004 Sep 15; 22(18):3705-12. Oh WK, Kantoff PW, Weinberg V, Jones G, Rini BI, Derynck MK, Bok R, Smith MR, Bubley GJ, Rosen RT, DiPaola RS, Small EJ. PMID: 15289492.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    283. Plasma levels of heat shock protein 70 in patients with prostate cancer: a potential biomarker for prostate cancer. Clin Prostate Cancer. 2004 Jun; 3(1):49-53. Abe M, Manola JB, Oh WK, Parslow DL, George DJ, Austin CL, Kantoff PW. PMID: 15279691.
      View in: PubMed   Mentions: 41     Fields:    Translation:Humans
    284. Parenteral glutamine supplementation does not reduce the risk of mortality or late-onset sepsis in extremely low birth weight infants. Pediatrics. 2004 May; 113(5):1209-15. Poindexter BB, Ehrenkranz RA, Stoll BJ, Wright LL, Poole WK, Oh W, Bauer CR, Papile LA, Tyson JE, Carlo WA, Laptook AR, Narendran V, Stevenson DK, Fanaroff AA, Korones SB, Shankaran S, Finer NN, Lemons JA, National Institute of Child Health and Human Development Neonatal Research Network. PMID: 15121931.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansCTClinical Trials
    285. To tap or not to tap: high likelihood of meningitis without sepsis among very low birth weight infants. Pediatrics. 2004 May; 113(5):1181-6. Stoll BJ, Hansen N, Fanaroff AA, Wright LL, Carlo WA, Ehrenkranz RA, Lemons JA, Donovan EF, Stark AR, Tyson JE, Oh W, Bauer CR, Korones SB, Shankaran S, Laptook AR, Stevenson DK, Papile LA, Poole WK. PMID: 15121927.
      View in: PubMed   Mentions: 46     Fields:    Translation:Humans
    286. A Phase II trial of flavopiridol (NSC #649890) in patients with previously untreated metastatic androgen-independent prostate cancer. Clin Cancer Res. 2004 Feb 01; 10(3):924-8. Liu G, Gandara DR, Lara PN, Raghavan D, Doroshow JH, Twardowski P, Kantoff P, Oh W, Kim K, Wilding G. PMID: 14871968.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    287. Radical prostatectomy lowers plasma vascular endothelial growth factor levels in patients with prostate cancer. Urology. 2004 Feb; 63(2):327-32. George DJ, Regan MM, Oh WK, Tay MH, Manola J, Decalo N, Duggan S, Dewolf WC, Kantoff PW, Bubley GJ. PMID: 14972483.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    288. A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813. Cancer. 2003 Dec 15; 98(12):2592-8. Oh WK, Halabi S, Kelly WK, Werner C, Godley PA, Vogelzang NJ, Small EJ, Cancer and Leukemia Group B 99813. PMID: 14669278.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCTClinical Trials
    289. Third international conference on innovations and challenges in prostate cancer: prevention, detection and treatment. J Urol. 2003 Dec; 170(6 Pt 2):S3-5. Carroll PR, Benaron DA, Blackledge G, Coakley FV, D'Amico AV, Higano CS, Iversen P, Kattan M, Nanus DM, Nelson JB, Oh WK, Roach M, Sellers WR, Smith MR, McMann MC, Kantoff PW. PMID: 14610403.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    290. The evolving role of chemotherapy and other systemic therapies for managing localized prostate cancer. J Urol. 2003 Dec; 170(6 Pt 2):S28-32; discussion S33-4. Oh WK. PMID: 14610407.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    291. Overtreatment of a patient with presumed recurrent prostate cancer based on false-positive prostate specific antigen results. J Urol. 2003 Oct; 170(4 Pt 1):1305. Leibowitz SB, Oh WK. PMID: 14501750.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    292. Association between peak serum bilirubin and neurodevelopmental outcomes in extremely low birth weight infants. Pediatrics. 2003 Oct; 112(4):773-9. Oh W, Tyson JE, Fanaroff AA, Vohr BR, Perritt R, Stoll BJ, Ehrenkranz RA, Carlo WA, Shankaran S, Poole K, Wright LL, National Institute of Child Health and Human Development Neonatal Research Network. PMID: 14523165.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    293. Immediate and delayed cord clamping in infants born between 24 and 32 weeks: a pilot randomized controlled trial. J Perinatol. 2003 Sep; 23(6):466-72. Mercer JS, McGrath MM, Hensman A, Silver H, Oh W. PMID: 13679933.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCTClinical Trials
    294. Does labor influence neonatal and neurodevelopmental outcomes of extremely-low-birth-weight infants who are born by cesarean delivery? Am J Obstet Gynecol. 2003 Aug; 189(2):501-6. Wadhawan R, Vohr BR, Fanaroff AA, Perritt RL, Duara S, Stoll BJ, Goldberg R, Laptook A, Poole K, Wright LL, Oh W. PMID: 14520225.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    295. Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular cancer: a long-term update. Urology. 2003 Aug; 62(2):324-7. Bhayani SB, Ong A, Oh WK, Kantoff PW, Kavoussi LR. PMID: 12893344.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    296. Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up. Urology. 2003 Jul; 62(1):99-104. Oh WK, Manola J, Bittmann L, Brufsky A, Kaplan ID, Smith MR, Kaufman DS, Kantoff PW. PMID: 12837431.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    297. Neoadjuvant doxil chemotherapy prior to androgen ablation plus radiotherapy for high-risk localized prostate cancer: feasibility and toxicity. Am J Clin Oncol. 2003 Jun; 26(3):312-6. Oh WK, Kaplan ID, Febbo P, Prisby J, Manola J, Kaufman DS, Kantoff PW. PMID: 12796607.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    298. Physician attitudes toward cytotoxic chemotherapy use in patients with advanced prostate carcinoma. Cancer. 2003 May 01; 97(9):2171-9. Oh WK, Tully P, Kantoff PW, Regan MM. PMID: 12712468.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    299. Male patients with diagnoses of both breast cancer and prostate cancer. Breast J. 2003 May-Jun; 9(3):208-12. Leibowitz SB, Garber JE, Fox EA, Loda M, Kaufman DS, Kantoff PW, Oh WK. PMID: 12752629.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    300. Neoadjuvant therapy before radical prostatectomy in high-risk localized prostate cancer: defining appropriate endpoints. Urol Oncol. 2003 May-Jun; 21(3):229-34. Oh WK. PMID: 12810211.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    301. Neoadjuvant therapy for high-risk localized prostate cancer. Curr Oncol Rep. 2003 May; 5(3):250-7. Yu EY, Oh WK. PMID: 12667424.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    302. Effect of parenteral glutamine supplementation on plasma amino acid concentrations in extremely low-birth-weight infants. Am J Clin Nutr. 2003 Mar; 77(3):737-43. Poindexter BB, Ehrenkranz RA, Stoll BJ, Koch MA, Wright LL, Oh W, Papile LA, Bauer CR, Carlo WA, Donovan EF, Fanaroff AA, Korones SB, Laptook AR, Shankaran S, Stevenson DK, Tyson JE, Lemons JA, National Institute of Child Health and Human Development Neonatal Research Network. PMID: 12600870.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    303. Transitional cell carcinoma of the upper uroepithelial tract. Clin Adv Hematol Oncol. 2003 Feb; 1(2):102-4; discussion 105. Michaelson MD, Kaufman DS, Oh WK. PMID: 16224387.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    304. Complementary and alternative therapies in prostate cancer. Semin Oncol. 2002 Dec; 29(6):575-84. Oh WK, Small EJ. PMID: 12516040.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    305. The evolving role of estrogen therapy in prostate cancer. Clin Prostate Cancer. 2002 Sep; 1(2):81-9. Oh WK. PMID: 15046698.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    306. Minimal ventilation to prevent bronchopulmonary dysplasia in extremely-low-birth-weight infants. J Pediatr. 2002 Sep; 141(3):370-4. Carlo WA, Stark AR, Wright LL, Tyson JE, Papile LA, Shankaran S, Donovan EF, Oh W, Bauer CR, Saha S, Poole WK, Stoll B. PMID: 12219057.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCTClinical Trials
    307. Secondary hormonal therapies in the treatment of prostate cancer. Urology. 2002 Sep; 60(3 Suppl 1):87-92; discussion 93. OH WK. PMID: 12231058.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    308. Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer. Urology. 2002 Sep; 60(3 Suppl 1):1-6. Carroll PR, Kantoff PW, Balk SP, Brown MA, D'amico AV, George DJ, Grossfeld GD, Johnson CS, Kelly WK, Klotz L, Lee WR, Lubeck DP, Mcleod DG, Oh WK, Pollack A, Sartor O, Smith MR, Hart C, Second International Conference on Newer Approaches to Androgen Deprivation Therapy (ADT) in Prostat. PMID: 12231036.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    309. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics. 2002 Aug; 110(2 Pt 1):285-91. Stoll BJ, Hansen N, Fanaroff AA, Wright LL, Carlo WA, Ehrenkranz RA, Lemons JA, Donovan EF, Stark AR, Tyson JE, Oh W, Bauer CR, Korones SB, Shankaran S, Laptook AR, Stevenson DK, Papile LA, Poole WK. PMID: 12165580.
      View in: PubMed   Mentions: 683     Fields:    Translation:Humans
    310. Whole-body hypothermia for neonatal encephalopathy: animal observations as a basis for a randomized, controlled pilot study in term infants. Pediatrics. 2002 Aug; 110(2 Pt 1):377-85. Shankaran S, Laptook A, Wright LL, Ehrenkranz RA, Donovan EF, Fanaroff AA, Stark AR, Tyson JE, Poole K, Carlo WA, Lemons JA, Oh W, Stoll BJ, Papile LA, Bauer CR, Stevenson DK, Korones SB, McDonald S. PMID: 12165594.
      View in: PubMed   Mentions: 60     Fields:    Translation:HumansAnimalsCTClinical Trials
    311. Changes in pathogens causing early-onset sepsis in very-low-birth-weight infants. N Engl J Med. 2002 Jul 25; 347(4):240-7. Stoll BJ, Hansen N, Fanaroff AA, Wright LL, Carlo WA, Ehrenkranz RA, Lemons JA, Donovan EF, Stark AR, Tyson JE, Oh W, Bauer CR, Korones SB, Shankaran S, Laptook AR, Stevenson DK, Papile LA, Poole WK. PMID: 12140299.
      View in: PubMed   Mentions: 197     Fields:    Translation:HumansCells
    312. Initial decline in hemoglobin during neoadjuvant hormonal therapy predicts for early prostate specific antigen failure following radiation and hormonal therapy for patients with intermediate and high-risk prostate cancer. Cancer. 2002 Jul 15; 95(2):275-80. D'Amico AV, Saegaert T, Chen MH, Renshaw AA, George D, Oh W, Kantoff PW. PMID: 12124826.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    313. Neurodevelopmental outcome of premature infants after antenatal phenobarbital exposure. Am J Obstet Gynecol. 2002 Jul; 187(1):171-7. Shankaran S, Papile LA, Wright LL, Ehrenkranz RA, Mele L, Lemons JA, Korones SB, Stevenson DK, Donovan EF, Stoll BJ, Fanaroff AA, Oh W, Verter J. PMID: 12114906.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    314. Diluted tincture of opium (DTO) and phenobarbital versus DTO alone for neonatal opiate withdrawal in term infants. J Pediatr. 2002 May; 140(5):561-4. Coyle MG, Ferguson A, Lagasse L, Oh W, Lester B. PMID: 12032522.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCTClinical Trials
    315. PC-SPES and prostate cancer. Urol Clin North Am. 2002 Feb; 29(1):59-66, viii. Oh WK, Small EJ. PMID: 12109356.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    316. Rapid rise of serum prostate specific antigen levels after discontinuation of the herbal therapy PC-SPES in patients with advanced prostate carcinoma: report of four cases. Cancer. 2002 Feb 01; 94(3):686-9. Oh WK, George DJ, Kantoff PW. PMID: 11857300.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    317. A phase II trial of interferon-alpha and toremifene in advanced renal cell cancer patients. Cancer Invest. 2002; 20(2):186-91. Oh WK, Manola J, George DJ, Fierman A, Fontaine-Rothe P, Morrissey S, Prisby J, Kaufman DS, Shapiro CL, Kantoff PW, Smith MR. PMID: 11901538.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    With one click, see people who:

    Mentor Faculty

    Run Clinical Trials

    Work in Global Health Equity

    Offer Student Projects

    See more options in the Advanced Search tab

    William's Networks
    Concepts (812)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (33)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (59)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-3-g1ef1264b on PROFILES-PWEB03.

    Copyright © The Regents of the University of California.